Methods of using RARγ agonists for cancer treatment
RARγ selective agonists expand TILs in vitro and enhance adoptive T cell therapy, addressing the challenge of ineffective cancer treatments by promoting CD8+ effector T cells and tumor shrinkage in cancers like triple-negative breast cancer.
Patent Information
- Application Number
- JP2024530570
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-23
- Filing Date
- 2022-11-23
- Publication Date
- 2024-11-08
AI Technical Summary
Current cancer treatments face challenges in determining which therapies are effective for specific cancer types, particularly for triple-negative breast cancer, due to uncertainties in the effects of retinoids on different RAR subtypes and the lack of specific treatments with minimal systemic toxicity.
The use of RARγ selective agonists to expand tumor-infiltrating lymphocytes (TILs) in vitro and administer them to patients, combined with adoptive T cell therapy, to enhance the immune response against cancer cells.
This approach promotes the expansion of CD8+ effector T cells and increases TILs, leading to significant tumor shrinkage and improved immune response without direct toxicity to tumor cells, offering a promising treatment for cancers like triple-negative breast cancer.
Smart Images

Figure 2024541472000085 
Figure 2024541472000086 
Figure 2024541472000087
Abstract
Description
[Technical field]
[0001] The present disclosure relates to methods of treating cancer with RARγ agonists.
[0002] (CROSS REFERENCE TO RELATED APPLICATIONS) This application claims priority to U.S. Provisional Application No. 63 / 282,547, filed November 23, 2022, the entire contents of which are incorporated by reference herein. [Background technology]
[0003] Retinoids are a class of small molecules that interact with the nuclear receptors retinoic acid receptors (RAR) and retinoid X receptors (RXR). Retinoids that interact with RXR are called rexinoids, and in some contexts, the term retinoid is used to refer to compounds that interact with RAR. Both RAR and RXR have three subtypes, α, β, and γ. Retinoids can act as either agonists or antagonists of these receptors. Some retinoids interact with both RAR and RXR and each of the subtypes, while other retinoids interact preferentially or specifically with certain receptor types or subtypes. Retinoids control the development and differentiation of multiple types of cells. Retinoids have pleiotropic actions that depend in part on the specific receptor types and subtypes that a particular retinoid activates or inhibits. Retinoids exhibit a degree of structural diversity. It is not possible to predict with any certainty which receptor type or subtype a particular retinoid will interact with or whether a particular retinoid will act as an agonist or antagonist.
[0004] There is some discrepancy in the scientific literature about what effects might be observed, leading to further uncertainty about what can be predicted from specific subtypes of retinoids. In tissue culture studies of leukemia cell lines, Perri et al. (Exp Cell Res. 327(2):183-191, 2014) found that RARα agonists and RARγ antagonists each inhibited cell proliferation, whereas RARγ antagonists and BCL-x L found that the combination of RARγ agonists with a dual antagonist of MCL-1 and MCL-2 was largely inhibitory. In contrast, Meister et al. (Anticancer Res. 18(3A):1777-1786, 1998) found that RARγ agonists had the greatest antiproliferative effect on neuroblastoma cell lines. In both studies, apoptosis was seen as the primary mechanism for inhibiting tumor cell proliferation. Cheung et al. (Biochem Biophys Res Commun. 229(1):349-54, 1996) studied the effects of RAR subtype-specific agents by transfecting neuroblastoma cell lines with each RAR subtype and concluded that RARβ expression was required for growth inhibition. Raffo et al. (Anticancer Res. 20(3A):1535-43,2000) observed some apoptotic activity against breast cancer cell lines with agonists of all three subtypes, but the greatest effect was from the RARα agonist. Compared to these in vitro experiments, it is less clear what effects any of these compounds may have in vivo and where the panoply of pleiotropic actions may play out.
[0005] Cancer treatments are constantly evolving and becoming more specific and sophisticated. Early non-surgical cancer treatments generally target rapidly dividing cells that are more susceptible to radiological or chemical attacks. Over time, more specific and less systemically toxic treatments have been developed. Some treatments appear to have broad applications, such as immune checkpoint inhibitors. Others target cancers that express specific antigens or other biomarkers involved in the control of proliferation or differentiation, including a number of monoclonal antibodies and kinase inhibitors. Although various cancer treatments are being developed, it is becoming increasingly difficult to determine which candidate treatments may be pursued productively and for which indications. Summary of the Invention [Problem to be solved by the invention]
[0006] Disclosed herein are methods for expanding tumor-infiltrating lymphocytes (TILs) in vitro and related methods for treating cancer comprising administering to a subject in need of treatment an effective amount of a RARγ selective agonist and / or the expanded TILs.
[0007] One embodiment is a method of treating cancer comprising administering to a patient in need of treatment an effective amount of a RARγ selective agonist having the structure: [ka] (GAG1) where R is H or C 1-6 R is an alkyl group, and the crossed double bond to the =N-OH group indicates that the stereochemistry is unspecified. However, in some embodiments, the E configuration of the =N-OH group is preferred. 7 From R 12 is independently 1-6 Alkyl, hydrogen atom, alkoxy group, halogen atom (e.g., F, Cl, or Br), nitro group, hydroxy group, OCF 3, or C.O.R. 13 (However, R 13 is C 1-6 Alkyl or CF 3 ) Y is oxygen, sulfur, or NR 14 (However, R 14 is C 1-6 alkyl), and R 16 is H or F.
[0008] In some embodiments, the RARγ selective agonist has the structure: [ka] (GA1E)
[0009] One aspect is a method of generating, differentiating, or expanding a number of TILs by contacting the TILs with a RARγ selective agonist. In some embodiments, the contacting comprises culturing the TILs in vitro in a medium supplemented with the RARγ selective agonist. In some embodiments, the contacting comprises administering the RARγ selective agonist to a subject having a tumor.
[0010] For the above aspects, in some embodiments, the RARγ selective agonist is selective in that it has no or negligible agonist activity for RARα at clinically relevant concentrations, hi some embodiments, the RARγ selective agonist is selective in that it has no or negligible agonist activity for both RARα and RARβ at clinically relevant concentrations.
[0011] In some embodiments, the RARγ selective agonist is a compound of the following structure: [ka] (GAG1) where R is H or C 1-6R is an alkyl group, and the crossed double bond to the =N-OH group indicates that the stereochemistry is unspecified. However, in some embodiments, the E configuration of the =N-OH group is preferred. 7 From R 12 is independently 1-6 Alkyl, hydrogen atom, alkoxy group, halogen atom (e.g., F, Cl, or Br), nitro group, hydroxy group, OCF 3 , or C.O.R. 13 (However, R 13 is C 1-6 Alkyl or CF 3 ) Y is oxygen, sulfur, or NR 14 (However, R 14 is C 1-6 alkyl), and R 16 is H or F.
[0012] In some embodiments, the RARγ selective agonist is 4-((1E,3E)-3-(3-(tert-butyl)-2-ethyl-benzofuran-5-yl)-3-(hydroxyimino)prop-1-en-1-yl)-3-fluorobenzoic acid (GA1E), having the following structure: [ka] (GA1E) In some embodiments, the RARγ selective agonist is 4-((1E,3Z)-3-(3-(tert-butyl)-2-ethyl-benzofuran-5-yl)-3-(hydroxyimino)prop-1-en-1-yl)-3-fluorobenzoic acid (GA1Z), having the following structure: [ka] (GA1Z)
[0013] In some embodiments, the RARγ selective agonist is a compound of the following structure: [ka] (GAG2) where R is H or C 1-6 The RARγ agonist is 3-fluoro-4-((1E,3E)-3-(hydroxyimino)-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)prop-1-en-1-yl)benzoic acid (GA2E), having the following structure, or a pharma- ceutically acceptable salt thereof. [ka] (GA2E) In some embodiments, the RARγ selective agonist is 3-fluoro-4-((1E,3Z)-3-(hydroxyimino)-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)prop-1-en-1-yl)benzoic acid (GAZ), having the structure: [ka] (GA2Z)
[0014] In some embodiments, the RARγ selective agonist is a compound of the following structure: [ka] (GAG3) where R is H or C 1-6 is alkyl, R 1 and R 2 are each independently H or C 1-6 is alkyl, R 3 and R 3’ are independently H or halogen (e.g., Cl, F, or Br), and (R 4 ) 2 is R 4 and R 4’which independently include H, halogen (e.g., Cl, F, or Br), C 1-6 Alkyl, or C 1-6 Alkoxy, X is O, S, CH 2 , C(R 5 ) 2 , or N.R. 6 (However, R 5 and R 6 are each independently H or C1-6 alkyl), the crossed double bond to the =N-OH group indicates unspecified stereochemistry, the COOR group is in the meta or para position, and the two R 4 groups occupy the remaining positions on the ring. In some embodiments, a COOR group in the para position is preferred. In some embodiments, the E configuration of the =N-OH group is preferred. In some embodiments, both R 1 is CH 3 In some embodiments, both R 2 is H. In some embodiments, X is C(R 5 ) 2 In some embodiments, both R 5 is CH 3 In some embodiments, one R 3 is H, and the other R 3 is F. In some embodiments, both R 4 is H. In some embodiments, R 3 and R 4 are H. In some embodiments, R is H. In some embodiments, R is methyl or ethyl. In some embodiments, the COOR group is in the para position. In some embodiments, the COOR group is in the meta position. In some embodiments, the =N-OH group is in the E configuration. In some embodiments, the =N-OH group is in the Z configuration. In certain embodiments, R is H, the carboxylic acid group is in the para position, and both R 1 is CH 3 and both R 2 is H and X is C(CH 3 ) 2 and R 3 and R4 are H and the =N-OH group is in the E configuration (GAEp). Some embodiments specifically include one or more particular substituents at one or more of the variable positions. Some embodiments specifically do not include one or more particular substituents at one or more of the variable positions.
[0015] In some embodiments, the RARγ selective agonist is CD437, CD2325, CD666, trifarotene, or BMS961.
[0016] One aspect is a method of treating cancer with TILs expanded with a RARγ agonist. In some embodiments, the RARγ agonist is administered to a subject with cancer to be treated.
[0017] In an alternative embodiment, T lymphocytes are expanded in an in vitro culture by exposing the culture to an RARγ agonist, and the T lymphocytes expanded with the RARγ agonist are administered to a subject with cancer to be treated as an adoptive T cell therapy. That is, the medium is supplemented with an RARγ agonist. The concentration of the RARγ agonist in the medium can range from 1 pM to 1 mM. In some embodiments, the concentration of the RARγ agonist in the medium is 0.5 nM. In some embodiments, the T lymphocytes are TILs isolated from a tumor explant from a subject. In some embodiments, the T lymphocytes are peripheral blood mononuclear cells (PBMCs). In some embodiments, the T lymphocyte culture comprises lethally irradiated tumor cells. In some embodiments, the lethally irradiated tumor cells are obtained from a subject to be treated. In some embodiments, the medium is supplemented with interleukin 2 (IL-2). In some embodiments, the expanded T lymphocytes are administered to the subject by injection, for example, by intravenous or intratumoral injection.
[0018] In some embodiments, the subject is a mammal. In some embodiments, the subject is a human. In some embodiments, the RARγ agonist is GA1E. In some embodiments, the RARγ agonist is GA2E.
[0019] For the above aspects, in some embodiments, the cancer is breast cancer. In some embodiments, the breast cancer is triple negative breast cancer. In some embodiments, the cancer is Her2 + In some embodiments, the cancer is breast cancer. In some embodiments, the cancer is lung cancer, e.g., non-small cell lung cancer. In some embodiments, the cancer is a solid tumor. In some embodiments, the cancer is a hematological cancer. In some embodiments, the cancer is a carcinoma, sarcoma, melanoma, glioblastoma, leukemia, lymphoma, myeloma, or plasma cell cancer.
[0020] In some embodiments, an effective amount of a RARγ agonist is from about 0.01 to about 300 mg / m 2 / day, although dosages below or above this exemplary range are also within the scope of the present disclosure. The daily dose is from about 0.5 to about 100 mg / m 2 / day, from about 1 to about 90 mg / m 2 / day, from about 5 to about 80 mg / m 2 / day, or at least about 0.02, 0.03, 0.05, 0.07, 0.1, 0.2, 0.3, 0.5, 0.7, 1, 2, 3, 5, 7, 10, 15, 20, 25, 30, 50, 70, or 100 mg / m 2 / day, or at most about 0.1, 0.2, 0.3, 0.5, 0.7, 1, 2, 3, 5, 7, 10, 15, 20, 25, 30, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 225, 250, 275, or 300 mg / m 2 / day, or a range defined by any two of the preceding values, in some embodiments, the effective amount for a human is from about 0.006 to about 200 mg / day or from about 1 to about 100 mg / day.
[0021] In some embodiments, the effective amount of the RARγ agonist is from about 0.27 μg / kg / day to about 8 mg / kg / day, although dosages below or above this exemplary range are also within the scope of the present disclosure. The daily dose may be from about 0.013 to about 2.7 mg / kg / day, from about 0.025 to about 2.5 mg / kg / day, from about 0.130 to about 22 mg / kg / day, or from about 0.0005, 0.0008, 0.001, 0.0013, 0.0020, 0.0025, 0.005, 0.0008, 0.0010, 0.0013, 0.0020, 0.0027, 0.005, 0.008, 0.010, 0.013, 0.020, 0.027, 0.05, 0.08, 0.1, 0.13, 0.2, 0.5, 0 0.0027, 0.005, 0.008, 0.010, 0.013, 0.020, 0.027, 0.05, 0.08, 0.1, 0.13, 0.2, 0.5, 0.8, 1.0, 1.3, 1.8, 2.0, or 2.7, 3.3, 4.0, 4.7, 5.4, 6.1, 6.8, 7.4, or 8.0 mg / kg / day, or a range defined by any two of the foregoing values.
[0022] For any aspect involving administering a RARγ selective agonist to a subject, in some embodiments, administration is performed periodically throughout the treatment period. That is, the RARγ agonist is administered at a time point that is regularly present within the treatment period. In some embodiments, the period is twice daily, once daily, every other day, every other day, or twice weekly. In some embodiments, administration is performed in repeated cycles throughout the treatment period. In some embodiments, a cycle includes 1) administering the RARγ selective agonist periodically for a first period, and 2) discontinuing administration of the RARγ selective agonist for a second period, after which a new cycle may be initiated. In some embodiments, the first period (during which the RARγ agonist is administered) is 10 to 15 days, or any integer number of days therein. In some embodiments, the second period (during which the administration of the RARγ agonist is discontinued) is 2 weeks to 1 month, or any integer number of days therein. In various embodiments, the duration of treatment ranges from the first administration of the RARγ agonist until a complete response is achieved, stable disease is obtained, or disease progression reoccurs after stable disease or regression.
[0023] For any aspect involving administering to a subject a RARγ selective agonist, some embodiments further include administering an inhibitor of regulatory T cells (Treg). In some embodiments, the inhibitor of Treg is a Treg depleting antibody. In various embodiments, the Treg depleting antibody is an anti-CD25 antibody, an anti-glucocorticoid-induced tumor necrosis factor-related protein (GITR) antibody, an anti-FoxP3 antibody, an anti-CCR 4 or an anti-folate receptor 4 antibody. In some embodiments, the inhibitor of Treg comprises an RARα antagonist.
[0024] For any aspect involving administering to a subject an RARγ selective agonist, some embodiments further include administering an RXR agonist having the structure: [ka] (XAG) where R is H or C 1-6 In some embodiments, the RXR agonist is 3,7-dimethyl-6(S),7(S)-methano,7-[1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphth-7-yl]2(E),4(E)heptadienoic acid (IRX4204).
[0025] For any aspect that includes administering to a subject a RARγ selective agonist, some embodiments further include administering CAR-T cells. In some embodiments, the RARγ selective agonist is a compound having the structure of GAG1 as defined above.
[0026] For any aspect involving administering to a subject a RARγ selective agonist, some embodiments further include administering an anti-PD-1 antibody or an anti-PD-L1 antibody.
[0027] For any aspect involving generating or expanding TILs by contacting the TILs with a RARγ selective agonist, some embodiments further include adding to the culture medium or administering an anti-PD-1 antibody or an anti-PD-L1 antibody, as appropriate.
[0028] One embodiment is a method of enhancing chimeric antigen receptor-T (CAR-T) cancer immunotherapy, comprising administering an effective amount of a RARγ selective agonist having the structure of GAG1 to a cancer patient who is receiving, has received, or will receive chimeric antigen receptor-T (CAR-T) cells.
[0029] One aspect is a compound having the structure of GAG1 as defined above. One embodiment is 4-((1E,3E)-3-(3-(tert-butyl)-2-ethyl-benzofuran-5-yl)-3-(hydroxyimino)prop-1-en-1-yl)-3-fluorobenzoic acid (GA1E). Some embodiments are pharma- ceutically acceptable salts of GA1E. In some embodiments, the C of GA1E is 1-6 Some embodiments are pharmaceutical compositions comprising GA1E or a salt or ester thereof.
[0030] One aspect is a method for the general synthesis of GAG1 according to the synthesis scheme of Figure 1. The complete synthesis begins with compound 1 and proceeds through intermediate compounds 2 through 5 to produce isomeric GAG1 species GA1E and GA1Z. Some embodiments are methods for synthesizing GAG1 species that include reacting compound 3 with n-BuLi and N-methoxyl-N-methylacetamide to produce intermediate compound 4. Some embodiments are methods for synthesizing GAG1 species that include reacting compound 4 with methyl 3-fluoro-4-formylbenzoate to produce intermediate compound 5. Some embodiments are methods for synthesizing GAG1 species by reacting compound 5 with hydroxylamine hydrochloride in the presence of an organic or inorganic base. In some embodiments, the base is pyridine.
[0031] One embodiment is intermediate compound 4, which has the structure: [ka] A further embodiment is a method for synthesizing compound 4 by reacting compound 3 with n-BuLi and N-methoxyl-N-methylacetamide.
[0032] One embodiment is intermediate compound 5, which has the structure: [ka] A further embodiment is a method for synthesizing compound 5 by reacting compound 4 with methyl 3-fluoro-4-formylbenzoate in the presence of a base such as NaOH. [Brief description of the drawings]
[0033] [Figure 1] FIG. 1 shows a scheme for the synthesis of the GAG1 species, GA1E and GA1Z. [Diagram 2] FIG. 2 shows a scheme for the synthesis of GAG1 species GAG1-1 and GAG1-2. [Diagram 3] 3A-B show the results of RARα and RARγ transcription activation assays of GA1E (FIG. 3A) and GA2E (FIG. 3B). [Figure 4] Figures 4A-B show the results of treatment of triple-negative breast cancer in a syngeneic immunocompetent mouse model with the RARγ selective agonist tazarotenic acid and GA2E versus vehicle control. Figure 4A shows the tumor volume and thus the inhibition of tumor growth over the course of the experiment in each of the three groups of the study. Figure 4B shows the body weight over the course of the experiment in each of the three groups of the study. [Diagram 5]Figures 5A-B show the results of flow cytometry analysis of tumors excised at the end of the study described in Example 3 for each dose of GA2E, tazarotenic acid, and vehicle control. Results are shown as both percentages (upper panel) and absolute numbers of cells / tumor (lower panel). Figure 5A shows the number of live cells in the tumor and their percentage of total cells (Live), the number of white blood cells and their percentage of live cells based on CD45 staining (CD45), the total number of T cells and their percentage of white blood cells based on CD3 staining (Tot T), and CD4+ T cells and their percentage of total T cells based on CD4 staining (CD4T). FIG. 5B shows the number of memory T helper cells and their percentage among total CD4+ cells based on staining for CD4 and intracellular IFNγ (TH IFNγ), the number of Th17 and their percentage among total CD4+ cells based on staining for CD4 and intracellular IL-17 (TH IL17), the number of regulatory T cells and their percentage among total CD4+ cells based on staining for CD4, CD25, and FOXP3 (Treg), CD8+ T cells and their percentage among total T cells based on CD8 staining (CD8T), and cytotoxic memory T cells and their percentage among CD8+ cells based on staining for CD8 and intracellular IFNγ (TC IFNγ). [Figure 6] Figures 6A-B show the change in body weight, as mass (Figure 6A) or percentage change (Figure 6B), from the first day of treatment (day 0) to the end of the study in Balb / c mice implanted with EMT6 triple-negative breast cancer cells and treated with GA2E at 10 mg / kg (squares), 25 mg / kg (equilateral triangles), or 50 mg / kg (crosses), and in control mice (diamonds). [Figure 7] FIG. 7 shows tumor growth in mm3 from the first day of treatment (day 0) to the end of the study in Balb / c mice implanted with EMT6 triple-negative breast cancer cells in mice treated with GA2E at 10 mg / kg (squares), 25 mg / kg (equilateral triangles), or 50 mg / kg (crosses) and in control mice (diamonds). [Figure 8]8A-C show the production of IFNγ (pg / ml) by recall antigen-stimulated PBMC treated with vehicle control or RARγ selective agonists (GA2E in FIG. 8A, GA3Ep in FIG. 8B, and tazarotenic acid in FIG. 8C). [Figure 9] Figures 9A-C show PBMC proliferation of recall antigen-stimulated CD8+ PBMCs treated with vehicle control or RARγ selective agonists (GA2E in Figure 9A, GA3Ep in Figure 9B, and tazarotenic acid in Figure 9C). [Figure 10] Figures 10A-B show the change in body weight, expressed as mass (Figure 10A) or percentage change (Figure 10B), from the first day of treatment (day 0) to the end of the study in control mice (diamonds) and GA2E-treated mice (squares) engrafted with a Her2+ breast cancer cell line (JIMT-1) and human PBMCs in NSG-B2M mice. [Figure 11] FIG. 11 shows tumor growth in mm3 from the first day of treatment (day 0) to the end of the study in control mice (diamonds) and NSG-B2M mice implanted with a Her2+ breast cancer cell line (JIMT-1) and human PBMCs in GA2E-treated mice (squares). [Figure 12] Figures 12A-E show flow cytometric T cell subset analysis of CD8+ TILs from NSG-B2M mice engrafted with Her2+ breast cancer cell line (JIMT-1) and human PBMCs in control (diamond) and GA2E-treated (square) mice on day 26 (end of study). The subsets were total CD8+ T cells (Figure 12A, TC), naive CD8+ T cells (Figure 12B, CD8 Naive), central memory CD8+ T cells (Figure 12C, CD8 TCM), effector memory CD8+ T cells (Figure 12D, CD8 TEM), and terminally differentiated effector CD8+ T cells (Figure 12E, CD8 TEFF). For significant differences between treated and control groups, * indicates P<0.05, *** indicates P<0.001, and no asterisk indicates P>0.05. [Figure 13]Figures 13A-C show flow cytometry biomarker analysis of CD8+ TILs from NSG-B2M mice engrafted with Her2+ breast cancer cell line (JIMT-1) and human PBMCs in control (diamond) and GA2E-treated (square) mice on day 26 (end of study). Subsets were PD-1+CD8+ T cells (Figure 13A, TC PD1), CD18β+CD8+ T cells (Figure 13B, TC CD18), and CD54+CD8+ T cells (Figure 13C, TC CD54). For significant differences between treated and control groups, ** indicates P<0.005, *** indicates P<0.001, and **** indicates P<0.0001. [Figure 14] Figures 14A-E show flow cytometric T cell subset analysis of CD4+ TILs from NSG-B2M mice engrafted with Her2+ breast cancer cell line (JIMT-1) and human PBMCs in control (diamond) and GA2E-treated (square) mice on day 26 (end of study). The subsets were total CD4+ T cells (Figure 14A, TH), naive CD4+ T cells (Figure 14B, CD4 Naive), central memory CD4+ T cells (Figure 14C, CD4 TCM), effector memory CD4+ T cells (Figure 14D, CD4 TEM), and terminally differentiated effector CD4+ T cells (Figure 14E, CD4TEFF). For significant differences between treated and control groups, * indicates P<0.05, *** indicates P<0.001, and no asterisk indicates P>0.05. [Figure 15] Figure 15A-D shows flow cytometry biomarker analysis of CD4+ TILs from NSG-B2M mice engrafted with Her2+ breast cancer cell line (JIMT-1) and human PBMCs in control (diamond) and GA2E-treated (square) mice on day 26 (end of study). The subsets were PD-1+CD8+ T cells (Figure 15A, TH PD1), CD18β+CD4+ T cells (Figure 15B, TH CD18), CD54+CD4+ T cells (Figure 15C, TH CD54), and Fox3P+CD4+ T cells (Figure 15D, Tregs). For significant differences between treated and control groups, * indicates P<0.05 and no asterisk indicates P>0.05. [Figure 16] FIG. 16 shows dose-response curves for cell viability of EMT6 cells grown in the presence of three RARγ agonists, GA1E (squares), GA2E (circles), and GA3Ep (equilateral triangles). [Figure 17] FIG. 17 shows dose-response curves for cell viability of Lewis Lung carcinoma (LLC) cells grown in the presence of three RARγ agonists, GA1E (squares), GA2E (circles), and GA3Ep (equilateral triangles). [Figure 18] FIG. 18 shows the change in body weight, expressed as mass (FIG. 18A) or percentage change (FIG. 18B), from the first day of treatment (day 0) to the end of the study in B57BL / 6 mice implanted with LLC cells and treated with GA2E at 10 mg / kg (squares) or 25 mg / kg (equilateral triangles), and in control mice (diamonds). [Figure 19] FIG. 19 shows tumor growth in mm3 from the first day of treatment (day 0) to the end of the study in B57BL / 6 mice implanted with LLC cells and treated with GA2E at 10 mg / kg (squares) or 25 mg / kg (equilateral triangles) and control mice (diamonds). [Figure 20] Figure 20 shows the results of flow cytometry analysis of LLC tumors excised at the end of the study described in Example 10 for vehicle control (column 1 of each panel) and for each administration of GA2E at doses of 10 mg / kg (column 2) and 25 mg / kg (column 3). Results are shown as both percentages (upper panels) and absolute numbers of cells per mg / tumor (lower panels). Shown are the number of live cells in the tumor and their percentage of total cells (Live), the number of white blood cells and their percentage of live cells based on CD45 staining (CD45), and the total number of T cells and their percentage of white blood cells based on CD3 staining (Tot T). [Figure 21]Figure 21 shows the results of flow cytometry analysis of LLC tumors excised at the end of the study described in Example 10 for vehicle control (column 1 of each panel) and each administration of GA2E at doses of 10 mg / kg (column 2) and 25 mg / kg (column 3). Results are shown as both percentages (upper panels) and absolute numbers of cells per mg / tumor (lower panels). Shown are CD4+ T cells and their percentages in total T cells (CD4+) based on CD4 staining, T helper cells (Thelper1) based on positive staining for CD4 and intracellular IFNγ, and regulatory T cells based on positive staining for CD4, CD25, and FOXP3. [Figure 22] Figure 22 shows the results of flow cytometry analysis of LLC tumors excised at the end of the study described in Example 10 for vehicle control (column 1 of each panel) and each administration of GA2E at doses of 10 mg / kg (column 2) and 25 mg / kg (column 3). Results are shown as both percentages (upper panels) and absolute number of cells per mg / tumor (lower panels). Shown are CD8+ T cells and their percentages in total T cells (CD8+) based on CD8 staining, cytotoxic T cells (Cytotoxic CD8) based on staining for CD8 and intracellular IFNγ, naive CD8+ T cells (CD8 naive) based on positive staining for CD8 and CD62L and negative staining for CD44, CD8+ central memory T cells (CD8 Tcm) based on positive staining for CD8, CD62L, and CD44, and CD8+ effector memory T cells (CD8 Tem) based on positive staining for CD8 and CD44 and negative staining for CD62L. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0034] Disclosed herein are methods for expanding tumor infiltrating lymphocytes (TILs) and related methods of treating cancer by administering to a subject in need of treatment an effective amount of a RARγ selective agonist.
[0035] As used herein, "RARγ selective agonist" refers to an RARγ agonist that has no or negligible agonist activity for RARα at a clinically relevant concentration. In some embodiments, the RARγ selective agonist is selective in that it has no or negligible agonist activity for both RARα and RARβ at a clinically relevant concentration. A "clinically relevant concentration" refers to the concentration in the blood (typically determined by assaying plasma or serum) of a patient receiving an effective dose of the RARγ selective agonist, or the concentration used in in vitro culture to generate, differentiate, or expand TILs, with respect to the method in which the RARγ selective agonist is used. In some embodiments, the EC for activation of RARγ is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 50 EC for activation of RARα or for activation of RARα and RARβ 50 at least 1 / 100 or at least 1 / 50 of
[0036] One embodiment is a method of treating cancer comprising administering to a patient in need of treatment an effective amount of a RARγ selective agonist having the structure: [ka] (GAG1) where R is H or C 1-6 R is an alkyl group, and the crossed double bond to the =N-OH group indicates that the stereochemistry is unspecified. However, in some embodiments, the E configuration of the =N-OH group is preferred. 7 From R 12 is independently 1-6 Alkyl, hydrogen atom, alkoxy group, halogen atom (e.g., F, Cl, or Br), nitro group, hydroxy group, OCF 3 , or C.O.R. 13 (However, R 13 is C 1-6 Alkyl or CF 3 ) Y is oxygen, sulfur, or NR 14 (However, R14 is C 1-6 alkyl), and R 16 is H or F. In some embodiments, R is methyl or ethyl. In some embodiments, R is H. In some embodiments, R 16 is F.
[0037] The synthetic scheme for GAG1 species is shown in FIGS.
[0038] In some embodiments, Y is O in the RARγ selective agonist having the structure of GAG1. [ka] (GAG1-1)
[0039] In some embodiments, in an RARγ selective agonist having the structure of GAG1, the =N-OH group is in the E configuration. [ka] (GAG1-2)
[0040] In some embodiments, the RARγ selective agonist having the structure of GAG1 has the structure: [ka] (GA1E)
[0041] As used herein, alkyl refers to a moiety consisting of carbon and hydrogen that does not contain any double or triple bonds. The alkyl may be a straight chain alkyl, a branched alkyl, a cycloalkyl, or a combination thereof. 1-6Alkyl means an alkyl group having from 1 to 6 carbon atoms, including, but not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, t-butyl, pentyl isomers, hexyl isomers, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and combinations thereof having in the range of 1 to 6 carbon atoms. These considerations apply equally to alkyl moieties or alkoxy groups.
[0042] For structures disclosed herein that contain an aromatic ring substituted with an R group, when the R group is an alkoxy group, one valence of the oxygen atom is attached to the aromatic ring and the other valence is attached to the alkyl portion of the alkoxy group.
[0043] One aspect disclosed herein is a method of generating, differentiating, or expanding TILs by contacting the TILs with a RARγ selective agonist. The RARγ agonist stimulates T cell effector function but not Treg cells, and thus may promote anti-cancer immune responses. In particular, the RARγ selective agonists described herein stimulate CD8 + It can promote the production and expansion of TILs. IL-2 has been used previously to expand TILs. In vitro culture leads to changes in the T cell receptor repertoire, and in vitro expanded TILs are typically infused with additional IL-2 as a growth factor. However, IL-2 also has various toxicities, some of which cause capillary leak syndrome caused by urinary loss, hypotension, and edema within hours of infusion, as well as fever, chills, myalgia, and nausea. Alternative agents for expanding TILs without causing substantial toxicity are a long-felt and unmet need.
[0044] As used herein, the term "TIL" refers primarily to lymphocytes that can be found within tumors. Such TILs can be isolated from expanded tumor tissue and expanded in vitro. TILs can also be found outside of tumors, as they still infiltrate from outside of tumors into tumors. Thus, it is also possible to culture PBMCs in vitro in the presence of tumor antigens (e.g., lethally irradiated tumor cells) to generate or expand T cells that have the ability to infiltrate into tumors. The methods of generating, differentiating, or expanding TILs encompass such uses of PBMCs.
[0045] In some embodiments, contacting the TIL with the RARγ selective agonist comprises culturing the TIL in vitro in a medium supplemented with the RARγ selective agonist. Procedures for culturing TIL are known to those skilled in the art. To summarize the basic procedure, the resected tumor tissue is minced into approximately 1-3 mm pieces. 3 The tumor tissue can be cultured in vitro for 3-6 weeks in appropriate medium, with half of the medium replaced every 2-3 days, and split at 80% confluence. During the first 1-3 weeks, tumor cells are lost from the culture medium. To expand the TILs more rapidly, anti-CD3 antibodies and a 100- to 200-fold excess of irradiated feeder cells (autologous or allogeneic) can be added to the culture medium. To support high cell density, 10 9 From 2 × 10 11 The TILs can be transferred to a bioreactor to achieve a population of cells, and the culture is continuously treated with a RARγ selective agonist.
[0046] Where the TILs are generated or expanded from PBMCs, in some embodiments the PBMCs are obtained from the subject to be treated (autologous). In another embodiment the PBMCs are obtained from an HLA-matched donor. In some embodiments the tumor cells are obtained from the subject to be treated, while in other embodiments the tumor cells are obtained from a different individual. In some embodiments the PBMCs and the tumor cells are obtained from the same individual. In some embodiments the individual is the subject to be treated. In some embodiments the PBMCs and the tumor cells are obtained from different individuals, e.g. the PBMCs can be autologous but cultured with tumor cells from an HLA-matched or allogeneic donor. In some embodiments the PBMCs (or TILs) are cultured with lethally irradiated tumor cells, while in alternative embodiments the culture medium comprises tumor cell lysates or purified or synthetic tumor antigens.
[0047] In some embodiments, the contacting comprises administering to the tumor-bearing subject a RARγ selective agonist.
[0048] One aspect disclosed herein is a method of treating cancer comprising providing TILs expanded with a RARγ selective agonist to a patient in need of treatment. In one embodiment, the RARγ selective agonist is administered to a subject with cancer to be treated. In an alternative embodiment, the TILs are expanded in culture by exposing the culture to a RARγ selective agonist, and the RARγ selective agonist expanded TILs are administered to a subject with cancer to be treated as adoptive T cell therapy. In some embodiments, the subject is a mammal. In some embodiments, the subject is a human. In some embodiments, the RARγ selective agonist is GAG1. In some embodiments, the RARγ selective agonist is GAG2. In some embodiments, the RARγ selective agonist is GAG3p. In some cases, the =N-OH group of GAG1, GAG2, or GAG3p is in the E configuration. In yet further embodiments, the RARγ selective agonist is any of the individual chemical species or collection of chemical species encompassed by the structures of GAG1, GAG2, or GAG3. Certain embodiments specifically do not include any of the individual chemical species or collection of chemical species encompassed by the structures of GAG1, GAG2, or GAG3.
[0049] For any related aspect, in some embodiments, the cancer is a solid tumor, carcinoma, sarcoma, or hematological cancer. For any related aspect, in some embodiments, the cancer is melanoma, glioblastoma, renal cell carcinoma, lung cancer, bladder cancer, breast cancer, cervical cancer, colon cancer, gallbladder cancer, laryngeal cancer, liver cancer, thyroid cancer, gastric cancer, salivary gland cancer, prostate cancer, pancreatic cancer, ovarian cancer, leukemia, lymphoma, myeloma, or plasma cell carcinoma. For any related aspect, in some embodiments, the cancer is breast cancer. In some embodiments, the breast cancer is triple negative breast cancer. In some embodiments, the cancer is Her2 + In some embodiments, the cancer is breast cancer, hi some embodiments, the cancer is lung cancer, e.g., non-small cell lung cancer, hi some embodiments, the subject in need of treatment is a human.
[0050] The growth of many types of breast cancer is stimulated by estrogen, progesterone, and epidermal growth factor (especially if the cancer expresses excess human epidermal growth factor receptor 2 (Her2)). Agents that antagonize these effects have proven effective in treating breast cancer. However, approximately 10-20% of breast cancers do not express estrogen receptors, progesterone receptors, or excess Her2. These cancers are therefore called "triple-negative breast cancers." Triple-negative breast cancers are typically more aggressive and have a worse prognosis than other types of breast cancer, in part due to fewer treatment options. Triple-negative breast cancers are also more likely to metastasize and recur after treatment. Breast cancers are graded on a three-point scale based on how similar they are to normal, healthy breast cells, with higher grades indicating less similarity to normal cells. Triple-negative breast cancers are often grade 3. Triple-negative breast cancers are usually "basal-like," meaning that they resemble the basal cells that line the milk ducts. Basal-like cancers tend to be more aggressive and higher grade. Triple-negative breast cancer tends to start at an earlier age, for example, before age 50, compared with other types of breast cancer, which are more commonly diagnosed in people over age 60. About 70% of cancers with BRCA mutations are triple-negative. These factors make triple-negative breast cancer a particularly challenging disease to treat.
[0051] Current treatments for triple-negative breast cancer include neoadjuvant chemotherapy (chemotherapy before surgical removal of the tumor), inhibitors of poly ADP-ribose polymerase (RARP) (such as olaparib), and immunotherapy (e.g. immunotherapy with PD-1 blockade, such as atezolizumab in combination with albumin-bound paclitaxel).
[0052] In some embodiments in which an RARγ selective agonist is administered to a subject, the effective amount is from about 0.01 to about 300 mg / m 2 / day, although dosages below or above this exemplary range are also within the scope of the present disclosure. The daily dose is from about 0.5 to about 100 mg / m 2 / day, from about 1 to about 90 mg / m 2 / day, from about 5 to about 80 mg / m 2 / day, or at least about 0.02, 0.03, 0.05, 0.07, 0.1, 0.2, 0.3, 0.5, 0.7, 1, 2, 3, 5, 7, 10, 15, 20, 25, 30, 50, 70, or 100 mg / m 2 / day, or at most about 0.1, 0.2, 0.3, 0.5, 0.7, 1, 2, 3, 5, 7, 10, 15, 20, 25, 30, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 225, 250, 275, or 300 mg / m 2 / day, or a range bounded by any two of the preceding values. These dosage amounts can be converted to the approximate human equivalent dosage in mg / kg / day by dividing by 37.
[0053] In some embodiments, the effective amount of the RARγ agonist is from about 0.27 μg / kg / day to about 8 mg / kg / day, although dosages below or above this exemplary range are also within the scope of the present disclosure. The daily dose may be from about 0.013 to about 2.7 mg / kg / day, from about 0.025 to about 2.5 mg / kg / day, from about 0.130 to about 22 mg / kg / day, or from about 0.0005, 0.0008, 0.001, 0.0013, 0.0020, 0.0025, 0.005, 0.0008, 0.0010, 0.0013, 0.0020, 0.0027, 0.005, 0.008, 0.010, 0.013, 0.020, 0.027, 0.05, 0.08, 0.1, 0.13, 0.2, 0.5, 0 0.0027, 0.005, 0.008, 0.010, 0.013, 0.020, 0.027, 0.05, 0.08, 0.1, 0.13, 0.2, 0.5, 0.8, 1.0, 1.3, 1.8, 2.0, or 2.7 mg / kg / day, or may be at most about 0.0027, 0.005, 0.008, 0.010, 0.013, 0.020, 0.027, 0.05, 0.08, 0.1, 0.13, 0.2, 0.5, 0.8, 1.0, 1.3, 1.8, 2.0, or 2.7, 3.3, 4.0, 4.7, 5.4, 6.1, 6.8, 7.4, or 8.0 mg / kg / day, or a range bounded by any two of the foregoing values. These dosage amounts can be converted to the approximate equivalent human dosage in mg / kg / day by dividing by 37.
[0054] In some embodiments, the effective amount for humans is about 0.006 to about 200 mg / day or about 1 to about 100 mg / day. In some embodiments, the daily dose is given in a single administration. In other embodiments, the daily dose is divided into multiple administrations, for example, two administrations separated by 9-15 hours, 10-14 hours, 11-13 hours, or 12 hours.
[0055] The RARγ selective agonist does not necessarily have to be present in the subject at therapeutic levels throughout the entire treatment, because the primary therapeutic effect of the RARγ selective agonist is indirect, promoting an immune response, the expansion of TILs, which persists even in the absence of the RARγ selective agonist. Because it takes time for an immune response to develop, the beneficial effect may not be observed until administration of the RARγ selective agonist is discontinued. Indeed, in some embodiments, it may be beneficial to have a drug holiday during which administration of the RARγ selective agonist is suspended. To the extent that administration of the RARγ selective agonist is associated with toxicity or other undesirable side effects, interruption of administration allows time for the subject to recover from the adverse effect rather than allowing the adverse effect to continue to worsen. As used herein, "interruption" refers to the cessation of administration of the drug with the intention and expectation of resuming administration at a later time, which is distinct from discontinuation with no plan to resume administration of the drug. Resumption of administration may be beneficial, as immune responses tend to wane over time. Thus, for any aspect involving administering a RARγ selective agonist to a subject, in some embodiments, administration is performed periodically throughout the treatment period. That is, the RARγ agonist is administered at regular time points within the treatment period. In some embodiments, the period is twice daily, once daily, every other day, every other day, or twice weekly. In some embodiments, administration is performed in repeated cycles throughout the treatment period. In some embodiments, a cycle includes 1) administering the RARγ selective agonist periodically for a first period, and 2) discontinuing administration of the RARγ selective agonist for a second period, after which a new cycle may be initiated. In some embodiments, the first period (during which the RARγ agonist is administered) is 10 to 15 days, or any integer number of days therein. In some embodiments, the second period (during which the administration of the RARγ agonist is discontinued) is 2 weeks to 1 month, or any integer number of days therein. In various embodiments, the duration of treatment ranges from the first administration of the RARγ agonist until a complete response is achieved, stable disease is obtained, or disease progression occurs.
[0056] The RARγ selective agonist may be administered to a subject by any suitable route of administration. In some embodiments, the RARγ selective agonist is administered orally. In some embodiments, the RARγ selective agonist is administered by injection or infusion, for example, intravenously, subcutaneously, or intratumorally. In some embodiments, the RARγ selective agonist is administered intranasally. In some embodiments, the RARγ selective agonist is administered by nasal or oral (pulmonary) inhalation.
[0057] Ex vivo expanded TILs are generally administered by infusion, for example, intravenously or intratumorally. However, in some embodiments, ex vivo expanded TILs are administered in a single bolus or divided into multiple boluses intravenously or intratumorally. In some embodiments, a RARγ selective agonist is included in the bolus or infusion along with the TILs. In various embodiments, the infusion may last for 30 minutes, an hour, several hours, a day, or several days.
[0058] In some embodiments, about 10 9 From > 10 11 For example, if the TIL is 1 x 10 10 From 2 × 10 11 is administered. The RARγ selective agonist may be used continuously in culture and included in the expanded TILs that are infused. The RARγ agonist may be administered to the patient after TIL infusion for a set period of time or until the tumor is eliminated or no further benefit is observed from the TILs.
[0059] In some embodiments, the RARγ selective agonist is used as a monotherapy, hi other embodiments, the RARγ selective agonist is used in combination with one of the current treatments, before, during, or after the other treatment.
[0060] RARγ selective agonist, CD8 +Promotes the expansion of effector TIL cells. CD8 + Consistent with what is generally known about effector cells, these cells express PD-1, which is a CD8 + It can act as a negative regulator of effector cell activity. Thus, in some embodiments, treatment with an RARγ selective agonist is combined with PD-1 blockade. Treatment with an RARγ selective agonist inhibits CD8 + PD-1 among TILs + It can also increase the presence of T cells. For this reason, in some embodiments, RARγ selective agonist treatment is combined with PD-1 blockade. Several products for PD-1 blockade, also called immune checkpoint inhibition, are undergoing clinical evaluation. These include the anti-PD-1 antibodies pembrolizumab, nivolumab, cemiplimab, dostallimab, tislelizumab, spartalizumab, camrelizumab, sintilimab, toripalimab, JTX-4014, INCMGA00012, AMP-514, and budigalimab, and the anti-PD-L1 antibodies atezolizumab, avelumab, durvalumab, embafolimab, CK-301, CS-1001, KN035SHR-1316, CBT-502, BGB-A333, and BMS-936559. Several non-antibody inhibitors of PD-L1 are also in development, including AUNP12 (a 29 amino acid long peptide), CA-170 (a small organic molecule), and BMS-986189 (a macrocyclic peptide). AMP-224 is a fusion protein of PD-L2 (also called B7-DC) and an antibody Fc region, which is being developed as an anti-PD-1 checkpoint inhibitor. Such antibodies constitute a means of PD-1 blockade.
[0061] One of the growing strategies for cancer treatment is chimeric antigen receptor T cell (CAR-T) therapy. CAR-T cells are effective artificial TILs. Thus, in some embodiments, treatment with a RARγ selective agonist as described herein is combined with CAR-T therapy. A RARγ selective agonist can enhance chimeric antigen receptor-modified immune cell (CAR-MIC) therapy as described in US Patent Application Publication No. 2019001563 and US Patent Application Publication No. 20180338940 (the teachings of which on enhancing CAR-MIC with RARγ agonists are incorporated herein by reference in their entirety). Thus, an embodiment is a method of enhancing CAR-MIC cancer immunotherapy, comprising administering a RARγ selective agonist having the structure of GAG1 to a cancer patient who is undergoing, has undergone, or will undergo CAR-MIC. In some cases, the CAR-MIC is a CAR-T cell.
[0062] For any aspect that includes administering to a subject a RARγ selective agonist, some embodiments further include administering an inhibitor of regulatory T cells (Treg). In some embodiments, the inhibitor of Treg is a Treg depleting antibody. In various embodiments, the Treg depleting antibody is an anti-CD25 antibody, an anti-GITR antibody, an anti-FoxP3 antibody, an anti-CCR 4 or an anti-folate receptor 4 antibody. In some embodiments, the inhibitor of Treg comprises an RARα antagonist.
[0063] For any aspect involving administering to a subject an RARγ selective agonist, some embodiments further include administering an RXR agonist having the structure: [ka] (XAG) where R is H or C 1-6 In some embodiments, R is alkyl. In some embodiments, R is methyl or ethyl. In some embodiments, R is H, i.e., the RXR agonist is 3,7-dimethyl-6(S),7(S)-methano,7-[1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphth-7-yl]2(E),4(E) heptadienoic acid, also known as IRX4204. Compounds having the structure of XAG have anti-cancer activity, as described in US Patent Application Publication No. 2008 / 0300312 and US Patent Application Publication No. 2020 / 0390736 (the teachings of which on the treatment of cancer with RXR agonists are incorporated herein by reference in their entirety). Treatment with RARγ selective agonists can have undesirable side effects, such as weight loss, which can be excessive, especially at high doses, as shown in some of the examples below. Compounds having the structure of XAG have anti-cachexia effects, as described in US Patent Publication No. 20070185055 (the entire teaching of which is incorporated herein by reference for treating cachexia with RXR agonists), which may offset or mitigate the side effects of RARγ agonists that contribute to potential excess weight loss. Therefore, for either or both of these reasons, in some embodiments, treatment with a RARγ selective agonist, as described herein, is combined with treatment with a suitable RXR agonist, such as IRX4204.
[0064] The average surface area of the human body is generally 1.9 m for an adult male. 2 , 1.6m for adult females 2 , and 1.33m for children aged 12-13. 2It is accepted that the RARγ selective agonist dose is 0.01 to 0.05. These values can be used to calculate the dose range for the dose of the RARγ selective agonist. The total daily dose of the RARγ selective agonist activator can be administered as a single dose or as two doses administered in a 24-hour cycle, 8 to 16 hours or 10 to 14 hours apart. For repeated administration over several days or longer, the treatment can be repeated until the desired suppression of the disease or disease symptoms occurs. However, other dosing schedules may be beneficial and are within the scope of this disclosure. The desired dose can be delivered by a single bolus administration of the composition, by multiple boluses of the composition, or by continuous infusion administration of the composition.
[0065] The RARγ selective agonist can be administered to a mammal by standard administration methods, including parenteral, oral, intravenous, intraperitoneal, subcutaneous, pulmonary, transdermal, intramuscular, intranasal, buccal, sublingual, or suppository administration.As used herein, the term "parenteral" includes intravenous, intramuscular, subcutaneous, rectal, vaginal, and intraperitoneal administration.The RARγ selective agonist is preferably suitable for oral administration, for example, as a pill, tablet, or capsule.
[0066] Administration may be continuous or intermittent. Dosage may be determined by the timing and frequency of administration. Thus, the RARγ selective agonist disclosed herein may be given daily, weekly, biweekly, or monthly for a period of time, followed by an optional drug holiday (drug-free period), and this drug administration / drug holiday cycle may be repeated as necessary. For example, the RARγ selective agonist may be administered daily for one week, then not administered for the remainder of the month, then administered for the next week, etc. In certain embodiments, the total daily dose of the RARγ agonist may be administered as a single dose, or as two doses administered in a 24-hour cycle, 8 to 16 hours or 10 to 16 hours apart.
[0067] The effectiveness of cancer therapy is typically measured in terms of “response.” Techniques for monitoring response can be similar to tests used to diagnose cancer, such as, but not limited to: · Masses or tumors associated with some lymph nodes can be felt and measured by physical examination. Some internal cancer tumors will show up on an x-ray or CT scan and can be measured with a ruler. Blood tests, including those measuring organ function, may be done. Tumor marker tests may be done for certain cancers.
[0068] Regardless of the test used, whether a blood test, cell count, or tumor marker test, the test is repeated at specific intervals so that the results can be compared with similar earlier tests.
[0069] Response to cancer treatment has several definitions. Complete Response: All of the cancer or tumor disappears. There is no evidence of disease. Tumor marker levels (if applicable) may fall within the normal range. Partial response: some shrinkage of the cancer but residual disease. Tumor marker levels (if applicable) decrease (or increase, depending on the tumor marker, as an indication of reduced tumor burden), but evidence of disease persists. Stable State: Cancer is not growing or shrinking. The amount of disease does not change. Tumor marker tests (if applicable) do not change significantly. Disease progression: The cancer grows. There is more disease than before treatment. Tumor marker tests (if applicable) show an increase in tumor markers.
[0070] Other measures of efficacy of cancer treatment include overall survival (i.e., the time from diagnosis or from the start of the treatment under evaluation to death from any cause), cancer-free survival (i.e., the length of time that cancer remains undetected following a complete response), and progression-free survival (i.e., the length of time that recurrent tumor growth is not detectable following disease stabilization or partial response).
[0071] There are two standard methods for assessing the success of solid cancer treatments in terms of tumor size (tumor burden): the WHO criteria and RECIST criteria. These methods measure solid tumors and compare the current tumor to past measurements or compare the changes to future measurements to modify the treatment plan. The WHO method measures the long and short axis of a solid tumor and calculates the product of these two measurements. The RECIST method measures only the long axis. If there are multiple solid tumors, the sum of all the long axis measurements is calculated. However, for lymph nodes, the short axis is measured instead of the long axis.
[0072] The term "treat" or "treatment" broadly includes any type of therapeutic activity, including the alleviation or prevention of disease or an aspect thereof in a human or other animal, or any activity that otherwise affects the structure or function of the human or other animal body. Therapeutic activities include administration of the medicaments, dosage forms, and pharmaceutical compositions described herein to a medical patient, whether by a medical practitioner, the patient himself, or another person, in particular by various therapeutic methods, and by methods of purifying, differentiating, or expanding TILs as disclosed herein. Therapeutic activities include orders, instructions, and advice of a medical practitioner, such as a physician, physician assistant, or clinical nurse, which are subsequently carried out by another medical practitioner or any other person, including the patient himself. This includes, for example, instructions that a patient should receive or a clinical laboratory should carry out, diagnostic procedures, such as for cancer treatment and staging, so that the patient can ultimately receive beneficial and appropriate treatment. In some embodiments, the ordering, directing, and advising aspects of medical activities may include recommending, inducing, or mandating that a particular drug or combination of drugs be selected for the treatment of a condition and that the drugs are actually used, such as by approving coverage for a drug, denying coverage for an alternative drug, including the drug in an accepted formulary or excluding an alternative drug, or providing incentives for the use of the drug, as may be done by an insurance company or pharmacy benefit management company. In some embodiments, medical activities may also include recommending, inducing, or mandating that a particular drug be selected for the treatment of a condition and that the drugs are actually used, as may be done by a policy or practice standard established by a hospital, clinic, health insurance organization, medical practice, or physician association, and the like. All of these orders, directions, and advice may be viewed as conditional receipt of the benefit of the treatment upon compliance with the instructions. In some cases, the patient may also receive an incentive for compliance with such orders, directions, or advice. In some cases, the medical practitioner may also receive an incentive for compliance with such orders, directions, or advice.
[0073] (RARγ selective agonist) One embodiment includes a RARγ selective agonist that is a compound having the structure: [ka] (GAG1) where R is H or C 1-6 However, in some embodiments, the E configuration of the =N-OH group is preferred. 7 From R 12 is independently 1-6 Alkyl, hydrogen atom, alkoxy group, halogen atom (e.g., F, Cl, or Br), nitro group, hydroxy group, OCF 3 , or C.O.R. 13 (However, R 13 is C 1-6 Alkyl or CF 3 ) Y is oxygen, sulfur, or NR 14 (However, R 14 is C 1-6 In some embodiments, R is methyl or ethyl. In some embodiments, R is H. In some embodiments, R is a pharmaceutical composition or formulation comprising a compound having the structure of GAG1, or a pharma- ceutical acceptable salt thereof. For any method aspect, in some embodiments, the RARγ selective agonist is a compound having the structure of GAG1, or a pharma- ceutical acceptable salt thereof.
[0074] In some embodiments, Y is O in the RARγ selective agonist having the structure of GAG1. [ka] (GAG1-1)
[0075] In some embodiments, in an RARγ selective agonist having the structure of GAG1, the =N-OH group is in the E configuration. [ka] (GAG1-2)
[0076] For any aspect, in some embodiments, the RARγ selective agonist is 4-((1E,3E)-3-(3-(tert-butyl)-2-ethyl-benzofuran-5-yl)-3-(hydroxyimino)prop-1-en-1-yl)-3-fluorobenzoic acid (GA1E), having the following structure: [ka] (GA1E)
[0077] In some embodiments, the RARγ selective agonist is 4-((1E,3Z)-3-(3-(tert-butyl)-2-ethylbenzofuran-5-yl)-3-(hydroxyimino)prop-1-en-1-yl)-3-fluorobenzoic acid (GA1Z), having the following structure: [ka] (GA1Z)
[0078] For any of the methods of use or any of the methods of generating, differentiating or expanding TILs, in some embodiments the RARγ selective agonist is a compound of the following structure or a pharma- ceutical acceptable salt: [ka] (GAG2) where R is H or C 1-6 R is alkyl, and the cross double bond to the =N-OH group indicates that the stereochemistry is unspecified. However, in some embodiments, the E configuration of the =N-OH group is preferred. In some embodiments, R is methyl or ethyl. In some embodiments, R is H. In some embodiments, R is methyl or ethyl.
[0079] In some embodiments, the RARγ selective agonist is 3-fluoro-4-((1E,3E)-3-(hydroxyimino)-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)prop-1-en-1-yl)benzoic acid (GA2E), having the following structure: [ka] (GA2E) In some embodiments, the RARγ selective agonist is 3-fluoro-4-((1E,3Z)-3-(hydroxyimino)-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)prop-1-en-1-yl)benzoic acid (GA2Z), having the following structure: [ka] (GA2Z)
[0080] For any of the methods of use or any of the methods of generating, differentiating or expanding TILs, in some embodiments the RARγ selective agonist is a compound of the following structure or a pharma- ceutical acceptable salt: [ka] (GAG3) where R is H or C 1-6 is alkyl, R 1 and R 2 are each independently H or C 1-6 is alkyl, R 3 and R 3’ are independently H or halogen (e.g., Cl, F, or Br), and (R 4 ) 2 is R 4 and R 4’ which independently include H, halogen (e.g., Cl, F, or Br), C 1-6 Alkyl, or C 1-6 Alkoxy, X is O, S, CH 2 , C(R5 ) 2 , or N.R. 6 (However, R 5 and R 6 are each independently H or C1-6 alkyl), the crossed double bond to the =N-OH group indicates unspecified stereochemistry, the COOR group is in the meta or para position, and the two R 4 groups occupy the remaining positions on the ring. In some embodiments, a COOR group in the para position is preferred. In some embodiments, the E configuration of the =N-OH group is preferred. In some embodiments, both R 1 is CH 3 In some embodiments, both R 2 is H. In some embodiments, X is C(R 5 ) 2 In some embodiments, both R 5 is CH 3 In some embodiments, one R 3 is H, and the other R 3 is F. In some embodiments, both R 4 is H. In some embodiments, R 3 and R 4 In some embodiments, all of R are H. In some embodiments, R is H. In some embodiments, R is methyl or ethyl. In some embodiments, the para position of the COOR group is preferred. In some embodiments, the E configuration of the =N-OH group is preferred. In some embodiments, both R 1 is CH 3 In some embodiments, both R 1 is H. In some embodiments, both R 2 is H. In some embodiments, X is C(R 5 ) 2 In some embodiments, X is CH 2 In some embodiments, both R 5 is CH 3 In some embodiments, both R 3 is H, while in other embodiments, one R3 is H and one R 3 is F. In some embodiments, both R 4 is H. In some embodiments, R 3 and R 4 are H. In some embodiments, the COOR group is in the para position. In some embodiments, the COOR group is in the meta position. In some embodiments, the =N-OH group is in the E configuration. In some embodiments, the =N-OH group is in the Z configuration. In certain embodiments, R is H, the carboxylic acid group is in the para position, and both R 1 is CH 3 and both R 2 is H and X is C(CH 3 ) 2 and R 3 and R 4 are H and the =N-OH group is in the E configuration (GAEp). Some embodiments specifically include one or more particular substituents at one or more of the variable positions. Some embodiments specifically include one or more of these alternatives, while other embodiments do not include one or more of these alternatives.
[0081] For GAG3, in one embodiment, the RARγ selective agonist has the structure: [ka] (GAG3p) Another embodiment has the following structure: [ka] (GAG3m)
[0082] For GAG3, in one embodiment, the RARγ selective agonist has the structure: [ka] (GAG3Ep)
[0083] In some embodiments, the RARγ selective agonist is a compound with the structure: [ka] (GA3Ep) In another embodiment, the RARγ selective agonist is a compound with the structure: [ka] (GA3Em)
[0084] For any of the foregoing RARγ selective agonists of this section that contain a COOR group, in certain embodiments, R is H. 1-6 In alkyl embodiments, the alkyl portion of the ester has in the range of 1 to 6 carbon atoms, including, but not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, t-butyl, pentyl isomers, hexyl isomers, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and combinations thereof having in the range of 1 to 6 carbon atoms. 1-6 Various subsets (including individual species) including linear, branched, and / or cyclic moieties of any length or set of lengths within the alkyl genus and combinations of these esters are contemplated as further distinct embodiments.
[0085] For any of the foregoing RARγ selective agonists in this section that contain a =N-OH group, some embodiments include either configuration of this group, while other embodiments include only the E configuration, and yet other embodiments include only the Z configuration.
[0086] For any of the method aspects of use, in certain embodiments the RARγ selective agonist is tazarotenic acid (selective for RARγ over RARα, but not over RARβ), CD437, CD2325, CD666, trifarotene, or BMS961. [ka] CD437 [ka] CD2325 [ka] CD666 [ka] Trifarotene [ka] BMS961
[0087] In some embodiments, the RARγ agonist is a selective RARγ selective agonist in that it has no or only negligible agonist activity for both RARα and RARβ at clinically relevant concentrations. In some embodiments, the RARγ agonist is a selective RARγ selective agonist in that it has no or only negligible agonist activity for RARα at clinically relevant concentrations. In various embodiments, the RARγ selective agonist has no or only negligible agonist activity for RARα or RARβ at a clinically relevant concentration when the KD of the agonist for RARγ is more than 10-, 20-, 50-, or 100-fold lower than the KD for the other RAR(s). The KD is typically determined by a binding assay. In various embodiments, the RARγ selective agonist is a selective agonist that has no or only negligible agonist activity for RARα at clinically relevant concentrations when the KD of the agonist for RARγ is more than 10-, 20-, 50-, or 100-fold lower than the KD for the other RAR(s). The KD is typically determined by a binding assay. In various embodiments, the RARγ selective agonist is a selective agonist that has no or only negligible agonist activity for RARα at clinically relevant concentrations. 50 EC for (one or more) other RARs 50 EC 50is typically determined by a binding assay, e.g., a transcriptional activation assay. In certain embodiments where no particular criteria for selectivity are stated, a RARγ selective agonist will meet at least one of these criteria, e.g., the least stringent.
[0088] These RARγ agonists constitute a means for activating RARγ or for generating, differentiating or expanding TILs. Certain embodiments specifically include one or more of the disclosed chemical genera, subgenera or species of these RARγ agonists. Certain embodiments specifically do not include one or more of the disclosed chemical genera, subgenera or species of these RARγ agonists.
[0089] (Example) The following non-limiting examples are presented merely for illustrative purposes to facilitate a more complete understanding of representative embodiments presently contemplated, and should not be construed as limiting any of the embodiments described herein.
[0090] Example 1 (GAG1 synthesis) The synthetic scheme for the synthesis of GAG1, GA1E, and GA1Z species is shown in FIG.
[0091] Ethyl-2-oxo-ethyl-5-bromo-salicylate-2-yl-butyrate To a solution of ethyl-5-bromo-salicylate (compound 1, 24.5 g, 100 mmol) in acetone (400 mL) was added ethyl-2-bromobutyrate (23.4 g, 120 mmol) and potassium carbonate (20.7 g, 150 mmol) and the mixture was stirred at ambient temperature for 24 hours. The solids were removed by filtration and the solvent was removed by distillation to give the title compound (not shown in Figure 1) as a yellow oil. Yield = 23.2 g.
[0092] 5-Bromo-2-ethyl-benzofuran(2H)-3-one (compound 2) To a cold (0° C.) solution of ethyl-2-oxo-ethyl-5-bromo salicylate-2-yl)-butyrate (23.2 g, 70.3 mmol) in anhydrous toluene (300 mL) was added 20% sodium ethoxide in ethanol (27 g, 80 mmol) in small portions (5 min). The cooling bath was removed and the reaction was stirred at ambient temperature for 12 h. The reaction mixture was washed with water (25 mL) and brine (50 mL). The organic layer was dried and the solvent was removed by distillation under vacuum. The crude product was purified by silica gel column chromatography (10% ethyl acetate in hexane) to give the title compound (compound 2) as a white solid. Yield=16.5 g.
[0093] 1 HNMR (CDCl 3 ):d1.09(triplet,3H),1.80-1.95(m,1H),2.05-2.20(m,1H),4.61(t,2),7.12(d,1H),7.70(dd,1H),7.83(d,1H).
[0094] 5-Bromo-3-t-butyl-2-ethyl-benzofuran (compound 3) To a cold (-78 °C) suspension of cerium chloride (25.41 g, 103 mmol) in THF (250 mL) was added a solution of t-BuMgCl in ether (2 M, 41.2 mL, 82.4 mmol) and the resulting mixture was stirred for 30 min. Then, a solution of 5-bromo-2-ethyl-benzofuran(2H)-3-one (compound 2) (16.5 g, 68.66 mmol) in THF (100 mL) was added and the mixture was stirred at ambient temperature for 30 min. The reaction was quenched by the addition of MeOH (-78 °C), diluted with ethyl acetate (100 mL) and diluted with NH 4 The mixture was washed with aqueous Cl, water, and brine (20 mL each). The organic layer was dried and the solvent was removed by distillation. The resulting residue was a mixture of tertiary alcohol and unreacted compound 2, which was used in the next step without further purification.
[0095] The mixture of crude tertiary alcohol (obtained above), dichloromethane (300 mL), and p-TSA (200 mg) were stirred at ambient temperature for 12 hours. The mixture was diluted with NaHCO 3 Washed with aqueous solution, water, and brine (100 mL each). The organic layer was dried and the solvent was removed by distillation. The residual crude product was purified by silica gel column chromatography (3% ethyl acetate / hexane) to give the title compound (Compound 3) as a colorless oil. Yield=2.8 g.
[0096] 1 HNMR (CDCl 3 ):d1.35(triplet,3H),1.54(s,9H),2.97(q,2H),7.28(d,1H),7.33(dd,1H),7.88(d,1H).
[0097] 1-(3-tert-butyl-2-ethyl-benzofuran-5-yl)-ethanone (compound 4) To a cold (-78°C) solution of 5-bromo-3-t-butyl-2-ethylbenzofuran (compound 3) (2.8 g, 10 mmol) in THF (60 mL) was added n-BuLi in hexane (2.5 M solution, 4.8 mL, 12 mmol). The mixture was gradually warmed to about 10°C over 50 min, then recooled to -78°C and N-methoxyl-N-methylacetamide (1.23 g, 12 mmol) was added via syringe (tight fit). The cooling was removed and the reaction was stirred at ambient temperature for 12 h. NH 4 The reaction was quenched by adding aqueous Cl solution, and the mixture was stirred for 15 min. The mixture was diluted with ethyl acetate (60 mL) and washed with water and brine (10 mL each). The organic layer was dried and the solvent was removed by distillation. The product (compound 4) was purified by silica gel column chromatography (7% ethyl acetate in hexane). Yield=2.1 g.
[0098] 1 HNMR (CDCl 3):d1.33(triplet,3H),1.55(s,9H),2.68(s,3H),2.97(q,2H),7.87(d,1H),8.41(d,2H).
[0099] 4-[(E)-3-(3-tert-butyl-2-ethyl-benzofuran-5-yl)-3-oxo-prop-1-enyl]-3-fluoro-benzoic acid (compound 5) Methyl 3-fluoro-4-formylbenzoate (1.56 g, 8.6 mmol) was added to a solution of 1-(3-tert-butyl-2-ethyl-benzofuran-5-yl)-ethanone (compound 4) (2.1 g, 8.6 mmol) in 10 mL of 1N sodium hydroxide and 20 mL of methanol. After stirring at room temperature for 18 h, the reaction mixture was acidified with 1N HCl and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were washed with brine (1 × 10 mL), dried (MgSO 4 ) and concentrated under reduced pressure. The product (compound 5) was purified by silica gel chromatography (50% ethyl acetate in hexanes). Yield 1.6 grams.
[0100] 1 HNMR (CDCl 3 ):d1.39(triplet,3H),1.60(s,9H),3.02(q,2H),7.32(s,1H),7.51(d,1H),7 .83(t,1H),7.85(d,1H),7.92(d,1H),7.99(d,1H),8.03(d,1H),8.52(d,1H).
[0101] 4-[(E,3E)-3-(3-tert-butyl-2-ethyl-benzofuran-5-yl)-3-hydroxyimino-prop-1-enyl]-3-fluorobenzoic acid (GA1E) To a 10 mL ethanolic solution of 4-[(E)-3-(3-tert-butyl-2-ethyl-benzofuran-5-yl)-3-oxo-prop-1-enyl]-3-fluoro-benzoic acid (compound 5), hydroxylamine hydrochloride (653 mg, 9.40 mmol) and pyridine (1.86 g, 23.5 mmol) were added. The reaction mixture was then heated at reflux for 6 h. After cooling to room temperature, the solvent was removed in vacuo and the residue was taken up in water. The aqueous layer was adjusted to pH 4-5 with 1N HCl and the product was isolated by filtration. Further purification was performed by silica gel chromatography (10% methanol / 1% triethylamine / dichloromethane). Yield = 98 mg of impure Z isomer (GA1Z) due to incomplete separation and 660 mg of pure E isomer (GA1E).
[0102] GA1E: 1 HNMR(DMSO-D6):d1.31(triplet,3H),1.50(s,9H),2.97(q,2H),6.95(d,1H),7.38(d ,1H),7.57(d,1H),7.71(d,1H),7.82(d,1H),7.86(s,1H),7.90(d,1H),7.97(t,1H).
[0103] Example 2 (Specificity of GA1E and GA2E binding and activity) Transcription activation assays were performed to test the specificity of the binding activity of GA1E and GA2E for RARα and RARγ. Retinoic acid receptor transcription activation activity and binding efficiency were determined essentially as described in U.S. Pat. Nos. 5,298,429 and 5,071,773, the entire teachings of which are incorporated herein by reference for transcription activation assays. Transcription activation assays used expression plasmids encoding full-length receptors for RARα and RARγ. Receptor plasmids containing a herpesvirus thymidine kinase promoter and appropriate retinoic acid receptor response elements (RAREs) were placed upstream of an open coding region encoding firefly luciferase.
[0104] The ability of GA1E and GA2E to activate RARα and RARγ in transcriptional activation assays was tested over a concentration range of 0.5 to 625 nM (GA2E) or 0.05 to 3320 nM (GA1E). GA1E induced less than 10% transcriptional activation for RARα over the entire concentration range, but induced more than 50% transcriptional activation for RARγ at concentrations ≥25 nM and more than 70% transcriptional activation at concentrations ≥125 nM (Figure 3A). GA2E induced more than 85% transcriptional activation at all tested concentrations and less than 10% transcriptional activation of RARα at concentrations ≤25 nM (Figure 3B).
[0105] Example 3 (Treatment of triple-negative breast cancer in mice with RARγ agonists) The RARγ agonists tazarotenic acid and GA2E were evaluated in the EMT6 syngeneic mouse breast cancer model. 5 EMT6 cells were injected into the mammary fat pad of immune-competent female Balb / c mice. Tumors were 50-150 mm 3 When the tumor reached a mean volume of 100 μg / kg, mice were matched by tumor size into control or treatment groups (n=10-11).
[0106] Mice were treated with 1 mg / ml tazarotenic acid or 21 daily doses of GA2E at 10 mg / kg or vehicle control starting on day 0. Tumor volumes were measured and mice were weighed on days 0, 1, 3, 6, 8, 10, 13, 15, 17, 20, and 21.
[0107] Both tazarotenic acid and GA2E inhibited tumor growth, with GA2E having greater efficacy (Figure 4A). Tumor growth inhibition was not noticeable until more than 10 days after treatment began. At the end of the study, tazarotenic acid inhibited tumor growth by 44% and GA2E inhibited it by 63%. While the vehicle control group showed little weight gain, both treatment groups experienced similar gradual weight loss between 15% and 20% (Figure 4B), indicating that the drugs are well tolerated and acceptable for use as cancer treatments.
[0108] Example 4 (RARγ selective agonist increases TILs in triple-negative breast cancer-derived tumors in mice) At the beginning and end of the study in Example 3, tumors were excised, cells disaggregated and dispersed without the use of proteases, stained with various agents, and subjected to flow cytometry. Figures 5A-B show the flow cytometry results, both as percentage of cells relative to the tumor and as cell numbers. Overall, only a minority of cells in the tumor were viable, as revealed by staining with FVS700 dye, which penetrates and stains necrotic cells (Figure 5A, "Live" panel). Of these live cells, a significant proportion were leukocytes (Figure 5A, "CD45" panel). Staining with anti-CD3 (Figure 5A, "Tot T" panel) revealed that, on average, only about 5% and 10% of the leukocytes were T cells for vehicle- and tazarotenic acid-treated mice, respectively, whereas, on average, about 30% of the leukocytes were T cells in tumors from GA2E-treated mice, a statistically significant difference. The majority of T cells were CD4 + (Fig. 5A, "CD4" panel), and most of them were expected to be helper cells. + Only a small proportion of the cells were T memory cells (based on intracellular staining for IFNγ, expected to be mostly TH1 memory cells) (Figure 5B, "TH IFNγ" panel), TH17 cells (based on intracellular staining for IL-17) (Figure 5B, "TH IL17" panel), or Treg cells (based on staining for CD25 and FoxP3) (Figure 5B, "Treg" panel). Approximately 25-30% of the T cells were CD8 + (Fig. 5B, "CD8 T" panel), and most were expected to be cytotoxic cells. Based on intracellular staining for IFNγ, the CD8 T cells were memory cells. + The T cell fraction (Figure 5B, "TC IFNγ" panel) was numerically increased in tumors from tazarotenic acid and GA2E-treated mice, although the difference from vehicle control animals was not statistically significant. Thus, GA2E treatment increased the number of TILs.
[0109] Example 5 Treatment of triple-negative breast cancer in mice with various doses of RARγ agonists The effect of increasing doses of GA2E was evaluated in an EMT6 triple-negative breast cancer model essentially as described above. Mice were orally dosed daily for 17 days with GA2E at 10 mg / kg (n=10), 25 mg / kg (n=10), or 50 mg / kg (n=11), or vehicle control (n=10), except that all mice in the 50 mg / kg group were sacrificed no later than day 12 due to excessive weight loss, as was one mouse in the 25 mg / ml group. Two mice in the vehicle control group had tumors >1500 mm 3 They were sacrificed on day 12.
[0110] Overall, the 10 mg / kg and 25 mg / kg groups showed acceptable well-tolerated cancer drugs, with only a short-term deviation to body weight loss of more than 10% for the 25 mg / kg dose (Figure 6A-B). The 25 mg / kg dose was somewhat more effective at inhibiting tumor growth than the 10 mg / kg dose. Tumor inhibition by the 50 mg / kg dose was not obviously different from the other doses during the limited time that the animals in that group were on the study (Figure 7). When scaled to humans based on body surface area, 10 mg / kg and 25 mg / kg in mice correspond to approximately 0.8 mg / kg and 2.0 mg / kg in humans, respectively.
[0111] Example 6 (RARγ-selective agonist promotes activation and proliferation of CD8+ memory T cells) Peripheral blood mononuclear cells (PBMCs) from cytomegalovirus (CMV)-positive donors were labeled with carboxyfluorescein succinimidyl ester (CFSE) and stimulated with 1 mg / ml CMV recall antigen. PBMCs were then treated with one of three different RARγ-selective agonists or vehicle (DMSO) control and incubated at 37°C, 5% CO 2 Culture supernatants were collected and assayed for IFNγ production, and PBMCs were assessed for cell proliferation by flow cytometry for CFSE dilution.
[0112] CFSE is a fluorescently reactive cell membrane permeable dye. After internalization, CFSE covalently modifies proteins and remains intracellularly for long periods of time. CFSE-modified proteins are generally shared equally between daughter cells with each cell division, so the fluorescence intensity of the cells drops by half with each cell division. Therefore, the decrease in the dye's fluorescence signal can be used as a measure of cell proliferation.
[0113] Administration of RARγ selective agonists, GA2E, GA3Ep, and tazarotenic acid, at concentrations ranging from 0.1 to 1000 nM, significantly increased IFNγ production relative to the vehicle control group (Figures 8A-C). + Cell proliferation was also increased in CD8 cells (Figure 9A-C). Although the increase in cell proliferation over background levels was small, + This increase is still highly significant, as only a small fraction of cells would be expected to be CMV specific.
[0114] Example 7 (RARγ selective agonist is human CD8 + Promotes effector TIL generation and tumor shrinkage (NSG-B2m model) The NSG-B2M mouse model is a severely immunocompromised animal with pathology of non-obese diabetes mellitus (NOD), severe combined immunodeficiency (SCID), IL-2 receptor gamma deficiency, and beta2 microglobulin deficiency. Human tumor cells can be readily engrafted in this model, as can cells from the human immune system to study various aspects of cancer immunotherapy. Thus, the human immune response against human tumors can be modeled in this system. Mammary fat pads of female NSG-B2M were inoculated with 5×10 6 cells suspended in 0.1 mL of phosphate-buffered saline (PBS) with an equal volume of Matrigel®. 6 The mice were injected with 100 JIMT-1 cells (a human breast cancer cell line). Once the tumors had grown to 100-200 mm 3 Once the volume reached 1 x 10, administer 1 x 10 subcutaneously to the right flank of the mouse. 7 Human PBMCs were transplanted (pre-randomized). PBMCs were obtained from two donors and were distributed equally between the groups. Tumors were 200-250 mm 3 When the mean tumor volume reached 100 mg / kg (approximately 3 days after PBMC injection), animals were matched by tumor volume to form treatment and control groups, and treatment was initiated. The first day of treatment was defined as day 0. Mice were orally administered 10% dimethyl sulfoxide (DMSO) in PBS at 10 mL / kg daily in the vehicle control group, and GA2E dissolved in 10% DMSO in PBS at 10 mg / kg daily in the treatment group.
[0115] Tumor volumes were measured twice weekly and on the day the study endpoint was reached. Mice were weighed twice weekly and on the day the study endpoint was reached. Animals that showed >10% weight loss from day 0 were given nutritional supplements with free access. Animals that showed >20% weight loss in any 7-day period or >30% weight loss from day 0 were considered moribund and euthanized.
[0116] The study endpoint was defined as a mean tumor volume (uncensored) of 1500 mm in the control group. 3If this occurred before day 28, treatment groups and individual mice were allowed to continue treatment and were measured until day 28. By day 28, the mean tumor volume (uncensored) in the control group was 1500 mm 3 If the endpoint was not reached, the endpoint for all animals was a mean tumor volume (uncensored) of 1500 mm in the control group by day 60 at the latest. 3 The date was the day the
[0117] GA2E-treated mice lost a significant amount of body weight by >10% on day 12 of the study (Figure 10A-B), so the animals were placed on a drug holiday from day 13 until the end of the study. No effect on tumor growth was observed while the mice were receiving GA2E, but there was tumor shrinkage from day 19 of the study onwards (Figure 11), with some mice showing tumor shrinkage from day 17 onwards (data not shown). These data are consistent with the antitumor effects of RARγ agonists not being due to a direct effect on the tumor cells themselves, but rather that RARγ agonists promote antitumor immunity.
[0118] Mice were sacrificed on day 26 of the study and tumors were collected and analyzed by flow cytometry. Statistical analysis was performed using ordinary one-way ANOVA with Tukey's test for significant differences between groups. Gates were set to identify single cells by forward light scatter, live cells as single cells based on side scatter and staining with Fixable Viability Dye eFluor™ 780 for vital staining, white blood cells from live cells based on side scatter and anti-CD45 staining, lymphocytes from white blood cells based on side and forward light scatter, and total T lymphocytes (tot T) from lymphocytes based on side scatter and anti-CD3 staining. Total T lymphocytes were identified as CD4+ T cells based on staining with anti-CD4 and anti-CD8 antibodies. + (TH) and CD8 + (TC) lymphocytes were separated and subsets were assessed. The following observations were made per mg of tumor tissue:
[0119] All CD8 +The concentration of lymphocytes was increased in GA2-treated tumors compared with the control group (Fig. 12A, P<0.001). + Cells, naive (CCR7 + CD45AR + ), T central memory (CCR7 + CD45AR - ), or T effector memory (CCR7 - CD45AR - ) did not change significantly (Fig. 12B, C, and D, respectively). - CD45AR + Terminally differentiated CD8 defined as + There was a significant increase in the concentration of T effector cells (Fig. S1E, P < 0.0001). CCR7 promotes migration to lymph nodes, and thus effector cells found in the periphery are CCR7 - Terminally differentiated CD8 + T effector cells, expected to be cytolytic, were specifically increased in TILs within shrinking tumors, consistent with the interpretation that the anticancer activity of RARγ agonists such as GA2E occurs via immune mechanisms rather than direct effects. + The concentration of TILs was also increased in GA2E-treated tumors compared to controls (Fig. 13A, P<0.0001; Fig. 13B, P<0.001; and Fig. 13C, P<0.01, respectively). Both CD18 and CD54 are involved in cell-cell adhesion and immune surveillance. These increases in TILs were due to the CD8 + This suggests improved efficiency of antigen recognition and formation of immunological synapses by T effector cells. PD-1 is involved in immune homeostasis and promotes downregulation of immune responses, for example, via apoptosis of effector cells expressing PD-1. + The increase in cells reflects an upregulation response. Therefore, antagonists of the PD-1 / PD-L axis (immune checkpoint inhibitors), such as anti-PD-1 and anti-PD-L1 antibodies, may further enhance the immune response promoted by RARγ agonists, such as GA2E.
[0120] All CD4 + Lymphocyte concentrations were decreased (Fig. 14A, P<0.05), and all subsets examined, including naive (CCR7 + CD45AR + ), T central memory (CCR7 + CD45AR - ), T Effector Memory (CCR7 - CD45AR - ), terminally differentiated CD4 + T effector cells (CCR7 - CD45AR + ) were also significantly different (Fig. 14B, C, and D, all P<0.05, and Fig. 14D, P>0.05, respectively). + The concentration of TILs was also increased in GA2-treated tumors compared with the control group (Figure 15A, P<0.05; Figure 15B, P<0.05; Figure 15C, P<0.05, and Figure 15D, P>0.05, respectively).
[0121] The effect of administration of the RARγ agonist GA2E in this model of human antitumor immune responses was to upregulate CD8 + The concentration of TILs, and in particular terminally differentiated effector cells, was significantly increased. In contrast, the CD4 + The concentration of TILs was decreased. + , CD8β + , and CD54 + CD8 + The concentration of TILs increased, whereas CD4 + All of these data suggest that CD4 + CD8 with decreased response + This is consistent with the promotion of effector cell-based antitumor responses by TILs. To the applicant's knowledge, CD8 + No other small molecule agent exists that specifically recruits effector cells, fulfilling a much-needed desire for such an effect in cancer therapy.
[0122] Tumor cells were also assessed by flow cytometry for expression of PD-L1, CD18β, CD58 (LFA-3), and Her2. Treatment with GA2E did not significantly alter the percentage of cells expressing these markers, consistent with the lack of direct effects of RARγ agonists on tumor cells.
[0123] Example 8 (Effect of RARγ agonists on in vitro culture of triple-negative breast cancer cell lines) EMT6 cells were cultured in vitro for 5 days with multiple concentrations of the RARγ agonists GA1E, GA2E, and GA3Ep, and viability was assessed by Cell Titer Glo assay® (Promega). The compounds had no effect at concentrations below 1 μM, but rapidly became toxic at concentrations above 10 μM (Figure 16). The IC 50 were 52 μM, 19 μM, and 101 μM for GA1E, GA2E, and GA3Ep, respectively. These data confirm that the anticancer effects of RARγ agonists observed in vivo most likely result from the promotion of TIL-based antitumor immune responses rather than a direct effect on tumor cells. That is, the tumor-inhibitory effects result from their promotion of TILs, since at the concentrations used, RARγ agonists did not directly inhibit tumor growth.
[0124] Example 9 (Effect of RARγ agonists on in vitro cultures of Lewis lung carcinoma cell lines) Lewis Lung Carcinoma (LCC) cells were cultured in vitro with multiple concentrations of the RARγ agonists GA1E, GA2E, and GA3Ep, and viability was assessed by Cell Titer Glo assay®. The compounds were ineffective at concentrations below 1 μM, but rapidly became toxic at concentrations above 10 μM (Figure 17). The IC 50were 96 μM, 46 μM, and 45 μM for GA1E, GA2E, and GA3Ep, respectively. These data confirm that the anticancer effects of RARγ agonists observed in vivo most likely result from the promotion of TIL-based antitumor immune responses rather than a direct effect on tumor cells. That is, the tumor-inhibitory effects result from their promotion of TILs, since at the concentrations used, RARγ agonists did not directly inhibit tumor growth.
[0125] Example 10 (RARγ selective agonist is human CD8 + Promotes effector TIL generation and tumor shrinkage (LLC model) The LLC model is based on a spontaneously occurring epidermoid carcinoma of the lung in C57BL / 6 mice 70 years ago. This syngeneic model has been useful in predicting clinical utility. 6-8 week old C57BL / 6 mice were inoculated with 3 × 10 5 LLC cells were subcutaneously injected in 0.1 mL. Mice were matched by tumor size for control and treatment groups, and treatment began (day 0) when tumors reached a mean tumor volume of 50-150 mm3. Three groups of 10 mice each were established: vehicle control, 10 mg / kg GA2E, and 25 mg / kg GA2E. Mice were orally dosed once daily for 13 days. Tumor volumes and body weights were measured on days 0, 2, 4, 6, 9, 11, and 13. Mice with a mean tumor volume >1500 mm3 were randomly dosed. 3 Therefore, the study was terminated on day 13 and tumors were analyzed by flow cytometry. Two animals in the 10 mg / kg group and one animal in the 25 mg / kg group were sacrificed prematurely due to tumor ulceration.
[0126] The 10 mg / kg dose of GA2E was well tolerated with minimal weight loss over the course of the study. The 25 mg / kg dose of GA2E was less well tolerated with steady weight loss over the course of the study, with weight loss exceeding 10% around day 10 (Figure 18A-B). Both doses of the drug inhibited tumor growth, but there was no significant difference in tumor inhibition between the effects of the two doses (Figure 19).
[0127] Mice were sacrificed on day 13 of the study and tumors were collected and analyzed by flow cytometry. Statistical analysis was performed using ordinary one-way ANOVA with Tukey's test for significant differences between groups. Gates were set to identify single cells by forward light scatter, live cells as single cells based on side scatter and staining with Fixable Viability Dye eFluor™ 780 for vital staining, white blood cells from live cells based on side scatter and anti-CD45 staining, lymphocytes from white blood cells based on side and forward light scatter, and total T lymphocytes (tot T) from lymphocytes based on side scatter and anti-CD3 staining. Total T lymphocytes were identified as CD4+ T cells based on staining with anti-CD4 and anti-CD8 antibodies. + (TH) and CD8 + (TC) lymphocytes were separated and subsets were evaluated (Figure 20). The following observations were made per mg of tumor tissue:
[0128] All CD8 + The concentration of lymphocytes was increased in GA2E-treated tumors compared to the control group (Figure 22, panel CD8+, P<0.05 for the 25 mg / kg dose). The concentration of cytotoxic cells was also increased (Figure 22, panel Cytotoxic CD8, P<0.05 for the 25 mg / kg dose), indicating that the concentration of effector memory CD8 cells in the tumors was increased. + The concentrations of T cells were also similar (Figure 22, panel CD8 Tem, P<0.01 for the 25 mg / kg dose). Naïve and central memory CD8 +The concentration of T cells was not significantly altered by treatment (Figure 22, panels CD8 Naïve and CD8 Tem, respectively). The concentrations of total CD4+ T cells, T helper cells, and regulatory T cells in the tumor were not significantly altered by treatment (Figure 21). However, the proportion of Treg cells, as a percentage of total T cells, was significantly decreased (Figure 21, panel Tregs, P<0.001). Thus, upon treatment with GA2E, the number of TILs in the tumor, with a phenotype that should be more effective at killing tumor cells, was expanded.
[0129] The example shows that RARγ agonists inhibit breast cancer (Her2 + We show that RARγ agonists inhibit tumor growth and promote TIL production with human and mouse lymphocytes in multiple cancer models, including breast and triple-negative breast cancer and lung cancer cell lines. Although RARγ agonists appear to have no tumor growth inhibitory effect in vitro, it is clear that the tumor growth inhibitory effect observed in vivo is due to increased production of TILs and promotion of antitumor activity.
[0130] Example 11 Pharmacological activation of RARγ signaling using RARγ agonists synergizes with immune checkpoint inhibitor antibodies in the rejection of B16 melanoma cells. The antitumor effect of administering an immune checkpoint inhibitor antibody (such as an anti-CTLA-4 antibody) in combination with 10 nM of a RARγ agonist disclosed herein is examined in C57BL / 6 mice engrafted with B16F10 tumor cells. Mice administered vehicle alone show no survival advantage over untreated control mice. Mice administered both an immune checkpoint inhibitor antibody and an RARγ agonist have improved survival at 50 days, indicating that the two agents cooperate to eliminate B16 melanoma cells. Surviving mice receiving the combination are resistant to rechallenge with live tumor cells, indicating effective formation of B16-specific memory cells. Importantly, anti-melanoma effects are obtained with this combination of drugs without signs of acute or delayed toxicity.
[0131] In closing, although aspects of the present specification have been emphasized with reference to specific embodiments, it should be understood that those skilled in the art will readily appreciate that these embodiments of the present disclosure are merely illustrative of the principles of the subject matter disclosed herein. It should therefore be understood that the subject matter of the present disclosure is in no way limited to the specific methods, procedures, and / or reagents, etc., described herein. Thus, various modifications or alterations to the subject matter disclosed or alternative configurations thereof are possible in accordance with the teachings of the present specification without departing from the spirit of the present specification. Finally, the terms used in the present specification are merely intended to describe specific embodiments and are not intended to limit the scope of the present invention, which is defined solely by the claims. Thus, the present invention is not limited to that precisely as shown and described.
[0132] Certain embodiments of the present invention are described herein, including the best way known to the inventors for carrying out the invention. Of course, variations on these described embodiments will be apparent to those skilled in the art in light of the foregoing description. The inventors expect that those skilled in the art will adopt such variations as appropriate, and intend that the invention can be practiced in ways other than as specifically disclosed herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, this invention includes any combination of the above-described embodiments in all possible variations thereof unless otherwise specified or otherwise clearly contradicted by context.
[0133] The collection of alternative embodiments, components, or steps of the invention should not be construed as limiting. Each group member is individually referenced and claimed and may be combined in any combination with other group members disclosed herein. For reasons of convenience and / or patentability, one or more members of a group may be added to or deleted from a group. When such addition or deletion occurs, the specification is deemed to include the group as so modified, and therefore satisfies the description requirement of all Markush groups set forth in the claims.
[0134] Unless otherwise specified, all numbers expressing properties, items, amounts, parameters, characteristics, terms, etc. used in the specification and claims should be understood in all cases as modified by the term "about". As used herein, the term "about" means that the property, item, amount, parameter, characteristic, or term so modified encompasses a range of plus or minus 10% above or below the numerical value of the stated property, item, amount, parameter, characteristic, or term. Thus, unless otherwise stated to the contrary, the numerical parameters set forth in this specification and the appended claims are approximations with a range of variation. While not attempting to limit the application of the doctrine of equivalents to the scope of the claims, at the very least, each numerical designation should be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and values setting forth the broad scope of the invention are approximations, the numerical ranges and values set forth in the specific examples are reported as precisely as possible. However, any numerical range or value inherently contains errors necessarily resulting from the standard deviation found in their respective testing measurements. The recitation of numerical ranges of values herein is merely intended to serve as a shorthand method of referring individually to each individual value falling within that range, and unless otherwise stated, each individual value of a numerical range is incorporated herein as if each was individually set forth herein.
[0135] As used in the context of the present description (particularly in the claims), the singular term "a," "an," or "the" should be construed to cover both the singular and the plural, unless otherwise stated herein or otherwise clearly contradicted by the context. All methods described herein can be performed in any suitable order, unless otherwise stated herein or otherwise clearly contradicted by the context. The use of any exemplary or exemplary language (e.g., "etc.") described herein is intended only to clarify the invention and does not impose limitations on the scope of the invention other than as described in the claims. Nothing in this disclosure should be construed as indicating any non-claimed element essential to the practice of the invention.
[0136] Certain embodiments described herein may be further limited in the claims using the terms "consisting of" or "consisting essentially of." When used in the claims, whether originally filed or added by amendment, the transitional phrase "consisting of" excludes any element, step, or ingredient not specified in the claim. The transitional phrase "consisting essentially of," whether originally filed or added by amendment, limits the scope of the claim to the specified materials or steps and those that do not materially affect the basic and novel characteristic(s). The claimed embodiments of the invention are essentially or explicitly described and enabled herein.
[0137] All patents, patent publications, and other documents referenced or identified in this specification are individually and expressly incorporated herein by reference in their entirety for the purpose of describing and disclosing, for example, the compositions and methods described therein that may be used in connection with the present invention. These documents are provided solely for their disclosure prior to the filing date of this specification. Nothing in this regard should be construed as an admission that the inventors are not entitled to antedate such disclosure by reason of prior invention or for any other reason. All representations as to the contents or statements as to data of these documents are based on the information available to the applicant and do not constitute any admission as to the accuracy of the contents or data of these documents.
[0138] [Note] [Appendix 1] A method of treating cancer comprising administering to a patient in need of treatment an effective amount of a RARγ selective agonist having the structure: [ka] (GAG1) (However, R is H or C 1-6 The cross-linked double bond to the =N-OH group indicates that the stereochemistry is unspecified, and R 7 From R 12 is independently 1-6 Alkyl, hydrogen atom, alkoxy group, halogen atom, nitro group, hydroxy group, OCF 3 , or C.O.R. 13 (However, R 13 is C 1-6 Alkyl or CF 3 ) where Y is oxygen, sulfur, or NR 14 (However, R 14 is C 1-6 alkyl), and R 16 is H or F.)
[0139] [Appendix 2] The method of claim 1, wherein the RARγ selective agonist has the following structure: [ka] (GA1E)
[0140] [Appendix 3] 3. The method of claim 1 or 2, wherein the cancer is a solid tumor.
[0141] [Appendix 4] The method of claim 3, wherein the cancer is breast cancer.
[0142] [Appendix 5] The method of claim 4, wherein the breast cancer is triple-negative breast cancer.
[0143] [Appendix 6] The breast cancer is Her2 + The method according to claim 4, wherein the cancer is breast cancer.
[0144] [Appendix 7] The method of claim 3, wherein the cancer is lung cancer.
[0145] [Appendix 8] The method of any one of appendix 1 to 7, wherein the effective amount is about 1 to about 100 mg / day.
[0146] [Appendix 9] 9. The method of any one of claims 1 to 8, further comprising administration of CAR-T cells.
[0147] [Appendix 10] 9. The method of any one of claims 1 to 8, further comprising administration of an immune checkpoint inhibitor.
[0148] [Appendix 11] A method of generating or expanding tumor-infiltrating lymphocytes (TILs) by contacting said TILs with a RARγ selective agonist.
[0149] [Appendix 12] 12. The method of claim 11, wherein the contacting comprises administering the RARγ selective agonist to a subject having cancer.
[0150] [Appendix 13] The method of claim 11, wherein the contacting comprises culturing the TIL in vitro in a medium supplemented with the RARγ selective agonist.
[0151] [Appendix 14] The method of claim 13, comprising isolating TILs from a tumor explant.
[0152] [Appendix 15] The method of claim 13, comprising culturing peripheral blood mononuclear cells (PBMCs) in vitro in the presence of irradiated tumor cells in a medium supplemented with the RARγ selective agonist.
[0153] [Appendix 16] 16. The method of claim 15, wherein the PBMCs and the irradiated tumor cells are obtained from the same individual.
[0154] [Appendix 17] 17. The method of any one of claims 13 to 16, wherein the culture medium is further supplemented with IL-2.
[0155] [Appendix 18] 18. The method of any one of claims 13 to 17, further comprising adding an anti-PD-1 antibody or an anti-PD-L1 antibody to the culture medium.
[0156] [Appendix 19] A method of treating cancer comprising injecting the TILs generated or expanded according to any one of claims 11 to 18 into a patient in need of such treatment.
[0157] [Appendix 20] A method of treating cancer comprising providing TILs expanded with a RARγ selective agonist to a patient in need of treatment.
[0158] [Appendix 21] The method of claim 20, comprising administering TILs cultured in vitro in a medium supplemented with the RARγ selective agonist.
[0159] [Appendix 22] 22. The method of claim 20 or 21, wherein the providing comprises administering to the patient the RARγ selective agonist.
[0160] [Appendix 23] 23. The method of any one of claims 20 to 22, wherein the cancer is a solid tumor.
[0161] [Appendix 24] 24. The method of claim 23, wherein the cancer is breast cancer.
[0162] [Appendix 25] 25. The method of claim 24, wherein the breast cancer is triple-negative breast cancer.
[0163] [Appendix 26] The breast cancer is Her2 + 25. The method of claim 24, wherein the cancer is breast cancer.
[0164] [Appendix 27] 25. The method of claim 24, wherein the cancer is lung cancer.
[0165] [Appendix 28] 28. The method of any one of claims 11 to 27, wherein the RARγ selective agonist is a compound of the following structure: or a pharma- ceutically acceptable salt thereof. [ka] (GAG3p) (where R is H or C 1-6 is alkyl, R 1 and R2 are each independently H or C 1-6 is alkyl, R 3 , R 3’ , R 4 , and R 4’ are independently H or F, and X is O, S, CH 2 , C(R 5 ) 2 , or N.R. 6 (However, R 5 and R 6 are each independently H or C1-6 alkyl), and the crossed double bond to the =N-OH group indicates that the stereochemistry is unspecified.
[0166] [Appendix 29] The method of claim 28, wherein the RARγ selective agonist is a compound of the following structure: or a pharma- ceutical acceptable salt thereof. [ka] (GA2E)
[0167] [Appendix 30] The method of claim 28, wherein the RARγ selective agonist is a compound of the following structure: or a pharma- ceutical acceptable salt thereof. [ka] (GA3Ep)
[0168] [Appendix 31] 31. The method of any one of claims 19 to 30, wherein the RARγ selective agonist is a compound of the following structure: or a pharma- ceutically acceptable salt thereof. [ka] (GAG1) (However, R is H or C 1-6 The cross-linked double bond to the =N-OH group indicates that the stereochemistry is unspecified, and R 7 From R 12 is independently 1-6Alkyl, hydrogen atom, alkoxy group, halogen atom, nitro group, hydroxy group, OCF 3 , or C.O.R. 13 (However, R 13 is C 1-6 Alkyl or CF 3 ) where Y is oxygen, sulfur, or NR 14 (However, R 14 is C 1-6 alkyl), and R 16 is H or F.)
[0169] [Appendix 32] The method of claim 31, wherein the RARγ selective agonist has the following structure: [ka] (GA1E)
[0170] [Appendix 33] 33. The method of any one of claims 1 to 10 and 19 to 32, wherein the method comprises administering to a subject the RARγ selective agonist, the administration occurring periodically throughout a treatment period.
[0171] [Appendix 34] 33. The method of any one of claims 1 to 10 and 19 to 32, wherein the method comprises administering to a subject the RARγ selective agonist, the administration occurring in repeated cycles throughout a treatment period.
[0172] [Appendix 35] 35. The method of claim 34, wherein one cycle of treatment comprises: 1) administering the RARγ selective agonist periodically for a first period of time; and 2) discontinuing administration of the RARγ selective agonist for a second period of time, after which a new cycle may be initiated.
[0173] [Appendix 36] 36. The method of claim 35, wherein the first period of time is 10 to 15 days, or any integer number therebetween.
[0174] [Appendix 37] 37. The method of claim 35 or 36, wherein the second period of time is from 2 weeks to 1 month, or any integer number of days therebetween.
[0175] [Appendix 38] 38. The method of any one of claims 33 to 37, wherein the periodic is daily.
[0176] [Appendix 39] 38. The method of any one of claims 33 to 37, wherein the regular period is twice daily.
[0177] [Appendix 40] 38. The method of any one of claims 33 to 37, wherein the periodicity is every other day.
[0178] [Appendix 41] 41. The method of any one of claims 33 to 40, wherein the treatment period extends from the first administration until a complete response is achieved.
[0179] [Appendix 42] 41. The method of any one of claims 33 to 40, wherein the treatment period extends from the first administration until the cancer re-progresses after stable disease or regression.
[0180] [Appendix 43] The method of any one of claims 1 to 10 and 19 to 42, further comprising administering an inhibitor of Treg cells.
[0181] [Appendix 44] The method of claim 43, wherein the Treg cell inhibitor comprises an RARα antagonist.
[0182] [Appendix 45] The method of claim 43, wherein the Treg cell inhibitor comprises a Treg-depleting antibody.
[0183] [Appendix 46] The Treg depleting antibody is an anti-CD25 antibody, an anti-GITR antibody, an anti-FoxP3 antibody, an anti-CCR 4 46. The method of claim 45, comprising an antibody or an anti-folate receptor 4 antibody.
[0184] [Appendix 47] The method of any one of claims 1 to 8 and 19 to 46, further comprising administration of an anti-PD-1 antibody or an anti-PD-L1 antibody.
[0185] [Appendix 48] 7. The method of any one of claims 1 to 10 and 19 to 46, further comprising administering an RXR agonist having the structure: [ka] (XAG) (However, R is H or C 1-6 It is an alkyl group.
[0186] [Appendix 49] The method of claim 48, wherein the RXR agonist is 3,7-dimethyl-6(S),7(S)-methano,7-[1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphth-7-yl]2(E),4(E)heptadienoic acid (IRX4204).
[0187] [Appendix 50] A method for enhancing chimeric antigen receptor-T (CAR-T) cancer immunotherapy, comprising administering to a cancer patient who is receiving, has received, or will receive CAR-T cells, an effective amount of a RARγ selective agonist having the following structure, or a pharma- ceutical acceptable salt thereof: [ka] (GAG1) (However, R is H or C 1-6 The cross-linked double bond to the =N-OH group indicates that the stereochemistry is unspecified, and R7 From R 12 is independently 1-6 Alkyl, hydrogen atom, alkoxy group, halogen atom, nitro group, hydroxy group, OCF 3 , or C.O.R. 13 (However, R 13 is C 1-6 Alkyl or CF 3 ) where Y is oxygen, sulfur, or NR 14 (However, R 14 is C 1-6 alkyl), and R 16 is H or F.)
[0188] [Appendix 51] A method for enhancing immune checkpoint inhibitor cancer immunotherapy, comprising administering to a cancer patient who is receiving, has received, or will receive an immune checkpoint inhibitor an effective amount of a RARγ selective agonist having the following structure, or a pharma- ceutical acceptable salt thereof: [ka] (GAG1) (However, R is H or C 1-6 The cross-linked double bond to the =N-OH group indicates that the stereochemistry is unspecified, and R 7 From R 12 is independently 1-6 Alkyl, hydrogen atom, alkoxy group, halogen atom, nitro group, hydroxy group, OCF 3 , or C.O.R. 13 (However, R 13 is C 1-6 Alkyl or CF 3 ) where Y is oxygen, sulfur, or NR 14 (However, R 14 is C 1-6 alkyl), and R 16 is H or F.)
[0189] [Appendix 52] A RARγ selective agonist of the following structure: or a pharma- ceutically acceptable salt thereof. [ka] (GAG1) (However, R is H or C 1-6 is alkyl, R 7 From R 12 is independently 1-6 Alkyl, hydrogen atom, alkoxy group, halogen atom, nitro group, hydroxy group, OCF 3 , or C.O.R. 13 (However, R 13 is C 1-6 Alkyl or CF 3 ) where Y is oxygen, sulfur, or NR 14 (However, R 14 is C 1-6 alkyl).
[0190] [Appendix 53] 53. The RARγ selective agonist of claim 52, wherein R is H, methyl, or ethyl.
[0191] [Appendix 54] 53. The RARγ selective agonist of claim 52, wherein Y is O.
[0192] [Appendix 55] A RARγ selective agonist according to claim 54, having the following structure: [ka] (GAG1-1)
[0193] [Appendix 56] 53. The RARγ selective agonist of claim 52, wherein the =N-OH group is in the E configuration.
[0194] [Appendix 57] A RARγ selective agonist according to claim 56, having the following structure: [ka] (GAG1-2)
[0195] [Appendix 58] The RARγ selective agonist according to claim 52, wherein the RARγ selective agonist is 4-((1E,3E)-3-(3-(tert-butyl)-2-ethyl-benzofuran-5-yl)-3-(hydroxyimino)prop-1-en-1-yl)-3-fluorobenzoic acid (GA1E) having the following structure: [ka] (GA1E)
[0196] [Appendix 59] The RARγ selective agonist according to claim 52, wherein the RARγ selective agonist is 4-((1E,3Z)-3-(3-(tert-butyl)-2-ethylbenzofuran-5-yl)-3-(hydroxyimino)prop-1-en-1-yl)-3-fluorobenzoic acid (GA1Z) having the following structure: [ka] (GA1Z)
[0197] [Appendix 60] A RARγ selective agonist having the structure: [ka] GAG2 (where R is H or C 1-6 (It is an alkyl group, and the crossed double bond to the =N-OH group indicates that the stereochemistry is unspecified.)
[0198] [Note 61] 61. The RARγ selective agonist of claim 60, wherein R is H, methyl, or ethyl.
[0199] [Appendix 62] 61. The RARγ selective agonist of claim 60, wherein the =N-OH group is in the E configuration.
[0200] [Appendix 63] The RARγ selective agonist according to claim 60, wherein the RARγ selective agonist is 3-fluoro-4-((1E,3E)-3-(hydroxyimino)-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)prop-1-en-1-yl)benzoic acid (GA2E) having the following structure: [ka] (GA2E)
[0201] [Appendix 64] The RARγ selective agonist according to claim 60, wherein the RARγ selective agonist is 3-fluoro-4-((1E,3Z)-3-(hydroxyimino)-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)prop-1-en-1-yl)benzoic acid (GA2Z) having the following structure: [ka] (GA2Z)
[0202] [Appendix 65] A RARγ selective agonist having the structure: [ka] GAG3 (where R is H or C 1-6 is alkyl, R 1 and R 2 are each independently H or C 1-6 is alkyl, R 3 and R 3’ are independently H or halogen, (R 4 ) 2 is R 4 and R 4’ These independently include H, halogen, C 1-6 Alkyl, or C 1-6 Alkoxy, X is O, S, CH 2 , C(R5 ) 2 , or N.R. 6 (However, R 5 and R 6 are each independently H or C1-6 alkyl), the crossed double bond to the =N-OH group indicates that the stereochemistry is unspecified, the COOR group is in the meta or para position, and the two R 4 groups occupy the remaining positions on the ring.
[0203] [Note 66] A RARγ selective agonist according to claim 65, having any of the following structures: [ka] GAG3p [ka] GAG3m [ka] (GAG3Ep)
[0204] [Appendix 67] A RARγ selective agonist according to claim 65, having any of the following structures: [ka] GA3Ep [ka] GA3Em
Claims
1. A method of treating cancer comprising administering to a patient in need of treatment an effective amount of an RARγ selective agonist having the structure: or a pharma- ceutically acceptable salt thereof. 【Chemistry 1】 (GAG1) (where R is H or C 1-6 alkyl, the crossed double bond to the =N-OH group indicates that the stereochemistry is unspecified, R 7 From R 12 is independently 1-6 Alkyl, hydrogen atom, alkoxy group, halogen atom, nitro group, hydroxy group, OCF 3 , or C.O.R. 13 (However, R 13 is C 1-6 Alkyl or CF 3 ) and Y is oxygen, sulfur, or NR 14 (However, R 14 is C 1-6 alkyl), and R 16 is H or F.)
2. 2. The method of claim 1, wherein the RARγ selective agonist has the following structure: 【Chemistry 2】 (GA1E)
3. 3. The method of claim 1 or 2, wherein the cancer is a solid tumor.
4. The method of claim 3 , wherein the cancer is breast cancer.
5. The method of claim 4, wherein the breast cancer is triple-negative breast cancer.
6. The breast cancer is Her2 + The method according to claim 4, wherein the cancer is breast cancer.
7. The method of claim 3 , wherein the cancer is lung cancer.
8. 8. The method of any one of claims 1 to 7, wherein the effective amount is from about 1 to about 100 mg / day.
9. The method of any one of claims 1 to 8, further comprising administration of CAR-T cells.
10. 9. The method of any one of claims 1 to 8, further comprising administration of an immune checkpoint inhibitor.
11. A method of generating or expanding tumor-infiltrating lymphocytes (TILs) by contacting said TILs with an RARγ selective agonist.
12. The method of claim 11 , wherein the contacting comprises administering the RARγ selective agonist to a subject having cancer.
13. The method of claim 11, wherein the contacting comprises culturing the TILs in vitro in medium supplemented with the RARγ selective agonist.
14. The method of claim 13, comprising isolating TILs from a tumor explant.
15. 14. The method of claim 13, comprising culturing peripheral blood mononuclear cells (PBMCs) in vitro in the presence of irradiated tumor cells in medium supplemented with the RARγ selective agonist.
16. The method of claim 15 , wherein the PBMCs and the irradiated tumor cells are obtained from the same individual.
17. The method according to any one of claims 13 to 16, wherein the medium is further supplemented with IL-2.
18. The method of any one of claims 13 to 17, further comprising adding an anti-PD-1 antibody or an anti-PD-L1 antibody to the culture medium.
19. A method of treating cancer comprising injecting the TILs generated or expanded according to any one of claims 11 to 18 into a patient in need of treatment.
20. A method of treating cancer comprising providing TILs expanded with an RARγ selective agonist to a patient in need of treatment.
21. The method of claim 20, comprising administering TILs cultured in vitro in medium supplemented with the RARγ selective agonist.
22. 22. The method of claim 20 or 21, wherein said providing comprises administering to said patient said RARγ selective agonist.
23. 23. The method of any one of claims 20 to 22, wherein the cancer is a solid tumor.
24. 24. The method of claim 23, wherein the cancer is breast cancer.
25. 25. The method of claim 24, wherein the breast cancer is triple-negative breast cancer.
26. The breast cancer is Her2 + 25. The method of claim 24, wherein the cancer is breast cancer.
27. 25. The method of claim 24, wherein the cancer is lung cancer.
28. 28. The method of any one of claims 11 to 27, wherein the RARγ selective agonist is a compound of the following structure: or a pharma- ceutically acceptable salt thereof. 【Chemistry 3】 (GAG3p) (where R is H or C 1-6 alkyl, R 1 and R 2 are each independently H or C 1-6 alkyl, R 3 , R 3’ , R 4 , and R 4’ are independently H or F, and X is O, S, CH 2 , C(R 5 ) 2 , or N.R. 6 (However, R 5 and R 6 are each independently H or C1-6 alkyl, and the crossed double bond to the =N-OH group indicates that the stereochemistry is unspecified.
29. 29. The method of claim 28, wherein the RARγ selective agonist is a compound of the following structure: or a pharma- ceutically acceptable salt thereof. 【Chemistry 4】 (GA2E)
30. 29. The method of claim 28, wherein the RARγ selective agonist is a compound of the following structure: or a pharma- ceutically acceptable salt thereof. 【Chemistry 5】 (GA3Ep)
31. 31. The method of any one of claims 19 to 30, wherein the RARγ selective agonist is a compound of the following structure: or a pharma- ceutically acceptable salt thereof. 【Chemistry 6】 (GAG1) (where R is H or C 1-6 alkyl, the crossed double bond to the =N-OH group indicates that the stereochemistry is unspecified, R 7 From R 12 is independently 1-6 Alkyl, hydrogen atom, alkoxy group, halogen atom, nitro group, hydroxy group, OCF 3 , or C.O.R. 13 (However, R 13 is C 1-6 Alkyl or CF 3 ) and Y is oxygen, sulfur, or NR 14 (However, R 14 is C 1-6 alkyl), and R 16 is H or F.)
32. 32. The method of claim 31 , wherein the RARγ selective agonist has the following structure: 【Chemistry 7】 (GA1E)
33. 33. The method of any one of claims 1 to 10 and 19 to 32, wherein the method comprises administering to a subject the RARγ selective agonist, the administration occurring periodically throughout a treatment period.
34. 33. The method of any one of claims 1 to 10 and 19 to 32, wherein the method comprises administering to a subject the RARγ selective agonist, the administration occurring in repeated cycles throughout a treatment period.
35. The method of claim 34, wherein one cycle of treatment comprises: 1) administering the RARγ selective agonist periodically for a first period of time; and 2) discontinuing administration of the RARγ selective agonist for a second period of time, after which a new cycle may be initiated.
36. 36. The method of claim 35, wherein the first period of time is from 10 to 15 days, or any integer number of days therebetween.
37. 37. The method of claim 35 or 36, wherein the second period of time is from two weeks to one month, or any integer number of days therebetween.
38. 38. The method of any one of claims 33 to 37, wherein the periodicity is daily.
39. 38. The method of any one of claims 33 to 37, wherein the regular period is twice daily.
40. 38. The method of any one of claims 33 to 37, wherein the periodicity is every other day.
41. 41. The method of any one of claims 33 to 40, wherein the treatment period extends from the first administration until a complete response is achieved.
42. 41. The method of any one of claims 33-40, wherein the treatment period extends from the first administration until the cancer re-progresses after stable disease or regression.
43. 43. The method of any one of claims 1 to 10 and 19 to 42, further comprising administering an inhibitor of Treg cells.
44. The method of claim 43, wherein the inhibitor of Treg cells comprises an RARα antagonist.
45. 44. The method of claim 43, wherein the inhibitor of Treg cells comprises a Treg depleting antibody.
46. The Treg depleting antibody is an anti-CD25 antibody, an anti-GITR antibody, an anti-FoxP3 antibody, an anti-CCR antibody, 4 46. The method of claim 45, comprising an antibody or an anti-folate receptor 4 antibody.
47. The method of any one of claims 1 to 8 and 19 to 46, further comprising administration of an anti-PD-1 antibody or an anti-PD-L1 antibody.
48. 47. The method of any one of claims 1-10 and 19-46, further comprising administering an RXR agonist having the structure: 【Chemistry 8】 (XAG) (where R is H or C 1-6 It is an alkyl group.
49. 49. The method of claim 48, wherein the RXR agonist is 3,7-dimethyl-6(S),7(S)-methano,7-[1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphth-7-yl]2(E),4(E)heptadienoic acid (IRX4204).
50. A method for enhancing chimeric antigen receptor-T (CAR-T) cancer immunotherapy, comprising administering to a cancer patient who is receiving, has received, or will receive CAR-T cells, an effective amount of an RARγ selective agonist having the following structure, or a pharma- ceutical acceptable salt thereof: 【Chemistry 9】 (GAG1) (where R is H or C 1-6 alkyl, the crossed double bond to the =N-OH group indicates that the stereochemistry is unspecified, R 7 From R 12 is independently 1-6 Alkyl, hydrogen atom, alkoxy group, halogen atom, nitro group, hydroxy group, OCF 3 , or C.O.R. 13 (However, R 13 is C 1-6 Alkyl or CF 3 ) and Y is oxygen, sulfur, or NR 14 (However, R 14 is C 1-6 alkyl), and R 16 is H or F.)
51. A method for enhancing immune checkpoint inhibitor cancer immunotherapy comprising administering to a cancer patient who is receiving, has received, or will receive an immune checkpoint inhibitor an effective amount of an RARγ selective agonist having the following structure, or a pharma- ceutical acceptable salt thereof: 【Chemistry 10】 (GAG1) (where R is H or C 1-6 alkyl, the crossed double bond to the =N-OH group indicates that the stereochemistry is unspecified, R 7 From R 12 is independently 1-6 Alkyl, hydrogen atom, alkoxy group, halogen atom, nitro group, hydroxy group, OCF 3 , or C.O.R. 13 (However, R 13 is C 1-6 Alkyl or CF 3 ) and Y is oxygen, sulfur, or NR 14 (However, R 14 is C 1-6 alkyl), and R 16 is H or F.)
52. An RARγ selective agonist of the structure: or a pharma- ceutically acceptable salt thereof. 【Chemistry 11】 (GAG1) (where R is H or C 1-6 alkyl, R 7 From R 12 is independently 1-6 Alkyl, hydrogen atom, alkoxy group, halogen atom, nitro group, hydroxy group, OCF 3 , or C.O.R. 13 (However, R 13 is C 1-6 Alkyl or CF 3 ) and Y is oxygen, sulfur, or NR 14 (However, R 14 is C 1-6 alkyl).
53. 53. The RARγ selective agonist of claim 52, wherein R is H, methyl, or ethyl.
54. 53. The RARγ selective agonist of claim 52, wherein Y is O.
55. 55. The RARγ selective agonist of claim 54 having the structure: 【Chemistry 12】 (GAG1-1)
56. 53. The RARγ selective agonist of claim 52, wherein said =N-OH group is in the E configuration.
57. 57. The RARγ selective agonist of claim 56 having the structure: 【Chemistry 13】 (GAG1-2)
58. The RARγ selective agonist of claim 52, wherein the RARγ selective agonist is 4-((1E,3E)-3-(3-(tert-butyl)-2-ethyl-benzofuran-5-yl)-3-(hydroxyimino)prop-1-en-1-yl)-3-fluorobenzoic acid (GA1E), having the following structure: 【Chemistry 14】 (GA1E)
59. The RARγ selective agonist of claim 52, wherein the RARγ selective agonist is 4-((1E,3Z)-3-(3-(tert-butyl)-2-ethylbenzofuran-5-yl)-3-(hydroxyimino)prop-1-en-1-yl)-3-fluorobenzoic acid (GA1Z) having the following structure: 【Chemistry 15】 (GA1Z)
60. An RARγ selective agonist having the structure: or a pharma- ceutically acceptable salt thereof. 【Chemistry 16】 GAG2 (where R is H or C 1-6 It is an alkyl group, and the crossed double bond to the =N-OH group indicates that the stereochemistry is unspecified.
61. 61. The RARγ selective agonist of claim 60, wherein R is H, methyl, or ethyl.
62. 61. The RARγ selective agonist of claim 60, wherein said =N-OH group is in the E configuration.
63. The RARγ selective agonist of claim 60, wherein the RARγ selective agonist is 3-fluoro-4-((1E,3E)-3-(hydroxyimino)-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)prop-1-en-1-yl)benzoic acid (GA2E) having the following structure: 【Chemistry 17】 (GA2E)
64. The RARγ selective agonist of claim 60, wherein the RARγ selective agonist is 3-fluoro-4-((1E,3Z)-3-(hydroxyimino)-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)prop-1-en-1-yl)benzoic acid (GA2Z), having the following structure: 【Chemistry 18】 (GA2Z)
65. An RARγ selective agonist having the structure: or a pharma- ceutically acceptable salt thereof. 【Chemistry 19】 GAG3 (where R is H or C 1-6 alkyl, R 1 and R 2 are each independently H or C 1-6 alkyl, R 3 and R 3’ are independently H or halogen, (R 4 ) 2 is R 4 and R 4’ These independently include H, halogen, C 1-6 Alkyl, or C 1-6 Alkoxy, X is O, S, CH 2 , C(R 5 ) 2 , or N.R. 6 (However, R 5 and R 6 are each independently H or C1-6 alkyl), the crossed double bond to the =N-OH group indicates that the stereochemistry is unspecified, the COOR group is in the meta or para position, and the two R 4 groups occupy the remaining positions on the ring.
66. 66. The RARγ selective agonist of claim 65 having any of the following structures: 【Chemistry 20】 GAG3p 【Chemistry 21】 GAG3m 【Chemical 22】 (GAG3Ep)
67. 66. The RARγ selective agonist of claim 65 having any of the following structures: 【Chemistry 23】 GA3Ep 【Chemistry 24】 G A3Em
